[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 57 of about 57
1. Tongson-Ignacio JE, Honda SA, Bhagavan NV: Insulinoma, a rare neuroendocrine tumor: a case report. Hawaii Med J; 2005 Jan;64(1):9-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Insulinoma, a rare neuroendocrine tumor: a case report.
  • We report a case of Insulinoma, a rare neuroendocrine tumor with an incidence of approximately four per 5 million.
  • This case demonstrates the characteristic clinical, biochemical and histological features of an insulinoma, a rare benign neuroendocrine tumor where early recognition is important to ensure proper surgical treatment and prevent serious adverse consequences.


2. Kaliszewski K, Bednarz W, Łukieńczuk T, Rzeszutko M, Boryń M, Olewiński R, Dawiskiba T, Spodzieja J, Dawiskiba J: Retroperitoneal tumours--analysis of own clinical material--a six-year retrospective study. Hepatogastroenterology; 2010 Jan-Feb;57(97):47-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Retroperitoneal tumours--analysis of own clinical material--a six-year retrospective study.
  • BACKGROUND/AIMS: Primary retroperitoneal tumours and retroperitoneal organs' tumours represent a variety of lesions that require different treatments and have various prognoses.
  • The aim of this study was to present the author's observations of the histological tumors types occurrence and their surgical treatment.
  • METHODOLOGY: One hundred twenty-three cases of retroperitoneal tumours were studied retrospectively in a 6-year period.
  • All cases were subjected to laparotomy with an aim to resect the tumour completely.
  • RESULTS: In the present study we observed primary retroperitoneal tumours like malignant neuroblastoma, paraganglioma, primitive neuroectodermal tumour, cavernous haemangioma and mucinous cystadenoma.
  • Among retroperitoneal organs' tumours pancreatic lesions present the majority of them.
  • There were 6 cases of neuroendocrine pancreatic tumours.
  • In adrenal glands we observed benign and malignant lesions like pheochromocytoma and fibrosarcoma.
  • All primary retroperitoneal tumours, except two cases of retroperitoneal fibrosis, were an bloc removed.
  • CONCLUSIONS: Primary retroperitoneal tumours in contrast to retroperitoneal organs' tumours occur very rare.
  • The clinical manifestations of all retroperitoneal tumours are not specific, so it causes a lot of difficulties in early diagnosis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20422870.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


3. Bapat U, Mackinnon NA, Spencer MG: Carcinoid tumours of the larynx. Eur Arch Otorhinolaryngol; 2005 Mar;262(3):194-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Carcinoid tumours of the larynx.
  • The larynx is a rare site of origin of neuroendocrine carcinomas.
  • They can be divided into typical, atypical and small cell tumours on the basis of their histopathological differentiation.
  • The tumour histology and prognosis correlate closely.
  • The typical carcinoid tumours are well differentiated with a benign course.
  • The atypical carcinoid tumours are poorly differentiated with an aggressive course.
  • The treatment of choice is adequate total excision of the lesion with neck dissection if there is clinical evidence of cervical lymphadenopathy and a careful follow-up so as to recognise and treat any metastatic spread.
  • [MeSH-major] Carcinoid Tumor / pathology. Laryngeal Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Laryngol Otol. 1986 Dec;100(12):1421-6 [3805883.001]
  • [Cites] Ann Otol Rhinol Laryngol. 1992 Aug;101(8):710-4 [1323230.001]
  • [Cites] J Exp Clin Cancer Res. 2002 Mar;21(1):5-13 [12071530.001]
  • [Cites] Ann Otol Rhinol Laryngol. 1987 May-Jun;96(3 Pt 1):315-21 [3300506.001]
  • [Cites] J Laryngol Otol. 1998 Sep;112(9):827-34 [9876371.001]
  • [Cites] Laryngoscope. 1985 Jun;95(6):715-9 [3889527.001]
  • [Cites] ORL J Otorhinolaryngol Relat Spec. 1991;53(4):210-9 [1653928.001]
  • [Cites] Otolaryngol Head Neck Surg. 1999 Apr;120(4):536-9 [10187951.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1991 Dec;117(12):1395-9 [1845268.001]
  • [Cites] Laryngoscope. 1995 Aug;105(8 Pt 1):789-94 [7630288.001]
  • [Cites] Ann Otol Rhinol Laryngol. 1989 Oct;98(10):780-90 [2552894.001]
  • [Cites] ORL J Otorhinolaryngol Relat Spec. 1991;53(4):194-209 [1891252.001]
  • [Cites] Laryngorhinootologie. 2000 Oct;79(10):573-8 [11089204.001]
  • [Cites] Cancer. 1982 Jan 15;49(2):343-9 [6119151.001]
  • [Cites] J Laryngol Otol. 1991 Dec;105(12):1031-5 [1664846.001]
  • [Cites] J Laryngol Otol. 1997 Jan;111(1):89-91 [9292144.001]
  • (PMID = 15164214.001).
  • [ISSN] 0937-4477
  • [Journal-full-title] European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
  • [ISO-abbreviation] Eur Arch Otorhinolaryngol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


Advertisement
4. Semaan MT, Megerian CA: Current assessment and management of glomus tumors. Curr Opin Otolaryngol Head Neck Surg; 2008 Oct;16(5):420-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Current assessment and management of glomus tumors.
  • PURPOSE OF REVIEW: To provide an overview on the recent advances in the diagnosis and treatment of glomus tumors (paragangliomas).
  • RECENT FINDINGS: The review focuses on the genetics of paragangliomas and discusses the role of newer therapeutic modalities in the management of jugulotympanic paragangliomas.
  • SUMMARY: Recent advances in the field of genetics allowed the identification of three main loci involved in hereditary paragangliomas.
  • The management of glomus tumors continues to be a challenging task.
  • [MeSH-major] Diagnostic Imaging / methods. Glomus Tumor / diagnosis. Glomus Tumor / surgery. Head and Neck Neoplasms / diagnosis. Head and Neck Neoplasms / surgery
  • [MeSH-minor] Angiography / methods. Female. Glomus Jugulare Tumor / diagnosis. Glomus Jugulare Tumor / epidemiology. Glomus Jugulare Tumor / surgery. Humans. Incidence. Magnetic Resonance Imaging / methods. Male. Neoplasm Staging. Paraganglioma / diagnosis. Paraganglioma / epidemiology. Paraganglioma / surgery. Prognosis. Radiographic Image Enhancement. Radiosurgery / methods. Risk Assessment. Survival Rate. Tomography, X-Ray Computed / methods

  • MedlinePlus Health Information. consumer health - Diagnostic Imaging.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18797283.001).
  • [ISSN] 1531-6998
  • [Journal-full-title] Current opinion in otolaryngology & head and neck surgery
  • [ISO-abbreviation] Curr Opin Otolaryngol Head Neck Surg
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 46
  •  go-up   go-down


5. Adair A, Oniscu A, Wigmore SJ: Post-surgical Pancreatitis Masquerading as Recurrent Neuroendocrine Cancer. J Surg Case Rep; 2010;2010(4):1
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Post-surgical Pancreatitis Masquerading as Recurrent Neuroendocrine Cancer.
  • Neuroendocrine tumours of the pancreas can have a spectrum of behaviour from relatively benign to aggressive.
  • We present an unusual case of an apparent local recurrence of previously resected neuroendocrine tumour in a young man who had undergone distal pancreatectomy.
  • Pathological analysis demonstrated focal post-surgical pancreatitis with radiological appearances bearing striking similarity to the original primary tumour.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © JSCR.
  • (PMID = 24946304.001).
  • [ISSN] 2042-8812
  • [Journal-full-title] Journal of surgical case reports
  • [ISO-abbreviation] J Surg Case Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC3649111
  •  go-up   go-down


6. Cai S, Liu H, Li WB, Ouyang YS, Zhang B, Li P, Wang XL, Zhang XY, Li JC, Jiang YX: Ultrasonographic features of medullary thyroid carcinoma and their diagnostic values. Chin Med J (Engl); 2010 Nov;123(21):3074-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Medullary thyroid carcinoma (MTC) is a rare malignant tumour and usually difficult to diagnose with ultrasound.
  • METHODS: We analyzed the sonographic features of 35 MTCs and 50 benign nodules with respect to nodular size, echogenecity, internal content, shape, height/width, border, peripheral halo, calcifications and colour flow pattern.
  • The differences in sonographic features between MTCs and benign nodules were analyzed with Chi square test.
  • The combination of multiple sonographic features is helpful, but not definitive, for the diagnosis of MTC.
  • [MeSH-minor] Adult. Aged. Carcinoma, Neuroendocrine. Female. Humans. Lymphatic Metastasis / diagnosis. Lymphatic Metastasis / ultrasonography. Male. Middle Aged. Young Adult

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21162958.001).
  • [ISSN] 0366-6999
  • [Journal-full-title] Chinese medical journal
  • [ISO-abbreviation] Chin. Med. J.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] Thyroid cancer, medullary
  •  go-up   go-down


7. Havekes B, van der Klaauw AA, Hoftijzer HC, Jansen JC, van der Mey AG, Vriends AH, Smit JW, Romijn JA, Corssmit EP: Reduced quality of life in patients with head-and-neck paragangliomas. Eur J Endocrinol; 2008 Feb;158(2):247-53
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reduced quality of life in patients with head-and-neck paragangliomas.
  • OBJECTIVE: The objective of this study was to assess the quality of life (QoL) in patients with head-and-neck paragangliomas ('glomus tumors').
  • METHODS: We assessed QoL in 82 patients with head-and-neck paragangliomas using four validated health-related questionnaires: Hospital Anxiety and Depression Scale, Multidimensional Fatigue Index (MFI-20), Short Form-36 (SF-36), and Nottingham Health Profile (NHP).
  • RESULTS: The QoL scores in the paraganglioma patients were significantly reduced in 12 out of the 21 subscales compared with own controls, and in 18 out of the 21 subscales compared with age- and sex-adjusted values derived from the previous studies.
  • In the MFI-20 questionnaire, patients reported more general fatigue, physical fatigue, mental fatigue, and a reduction in activity and motivation.
  • General health perception, pain, and physical functioning were reported to be worse in the paraganglioma patients on the SF-36 scale.
  • CONCLUSION: QoL is considerably reduced in patients with head-and-neck paragangliomas.

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18230833.001).
  • [ISSN] 1479-683X
  • [Journal-full-title] European journal of endocrinology
  • [ISO-abbreviation] Eur. J. Endocrinol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


8. Dietrich CF, Jenssen C, Allescher HD, Hocke M, Barreiros AP, Ignee A: [Differential diagnosis of pancreatic lesions using endoscopic ultrasound]. Z Gastroenterol; 2008 Jun;46(6):601-17
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Differential diagnosis of pancreatic lesions using endoscopic ultrasound].
  • The most common pancreatic tumour is the ductal adenocarcinoma.
  • Many other benign and malignant pancreatic neoplasms have to be recognised and now account for more than 50 % of the pancreatic lesions seen in our daily routine.
  • An improved differential diagnosis is, therefore, mandatory and will be discussed in this review.
  • [MeSH-minor] Biopsy, Fine-Needle. Carcinoma, Pancreatic Ductal / pathology. Carcinoma, Pancreatic Ductal / ultrasonography. Cell Transformation, Neoplastic / pathology. Cystadenocarcinoma, Mucinous / pathology. Cystadenocarcinoma, Mucinous / ultrasonography. Cystadenoma, Mucinous / pathology. Cystadenoma, Mucinous / ultrasonography. Cystadenoma, Papillary / pathology. Cystadenoma, Papillary / ultrasonography. Cystadenoma, Serous / pathology. Cystadenoma, Serous / ultrasonography. Diagnosis, Differential. Humans. Neuroendocrine Tumors / pathology. Neuroendocrine Tumors / ultrasonography. Pancreas / pathology. Pancreas / ultrasonography. Pancreatic Pseudocyst / pathology. Pancreatic Pseudocyst / ultrasonography. Pancreatitis / pathology. Pancreatitis / ultrasonography. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18537088.001).
  • [ISSN] 0044-2771
  • [Journal-full-title] Zeitschrift für Gastroenterologie
  • [ISO-abbreviation] Z Gastroenterol
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 212
  •  go-up   go-down


9. Rott G, Biggemann M, Pfohl M: Embolization of an insulinoma of the pancreas with trisacryl gelatin microspheres as definitive treatment. Cardiovasc Intervent Radiol; 2008 May-Jun;31(3):659-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Insulinomas are rare, mostly benign neuroendocrine tumors, originating in 99% of cases from the pancreas, that synthesize and secrete insulin, causing symptomatic hypoglycemia.

  • Genetic Alliance. consumer health - Insulinoma.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • Hazardous Substances Data Bank. GELATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17922161.001).
  • [ISSN] 1432-086X
  • [Journal-full-title] Cardiovascular and interventional radiology
  • [ISO-abbreviation] Cardiovasc Intervent Radiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Acrylic Resins; 0 / trisacryl gelatin microspheres; 9000-70-8 / Gelatin
  •  go-up   go-down


10. Kemeny AA: Contemporary management of jugular paragangliomas (glomus tumours): microsurgery and radiosurgery. Acta Neurochir (Wien); 2009 May;151(5):419-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Contemporary management of jugular paragangliomas (glomus tumours): microsurgery and radiosurgery.
  • [MeSH-major] Glomus Jugulare Tumor / surgery. Neoplasm Recurrence, Local / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Acta Neurochir (Wien). 2009 May;151(5):423-6 [19296050.001]
  • (PMID = 19296051.001).
  • [ISSN] 0942-0940
  • [Journal-full-title] Acta neurochirurgica
  • [ISO-abbreviation] Acta Neurochir (Wien)
  • [Language] eng
  • [Publication-type] Comment; Editorial
  • [Publication-country] Austria
  •  go-up   go-down


11. Rimbot A, Mounayer C, Loureiro C, Queiroz C, Kadziolka K, Spelle L, Piotin M, Bozorg-Grayeli A, Moret J: [Preoperative mixed embolization of a paraganglioma using Onyx]. J Neuroradiol; 2007 Dec;34(5):334-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Preoperative mixed embolization of a paraganglioma using Onyx].
  • [Transliterated title] Embolisation préopératoire par abord mixte d'un paragangliome à l'aide d'Onyx.
  • Paragangliomas, or glomus tumors, are highly vascular benign tumors of the head and neck.
  • Preoperative embolization can reduce morbidity, and several techniques have been described using arterial injection of particles or of cyanoacrylate directly into the tumor.
  • This case report is of a patient treated by surgery using a new technique-preoperative embolization involving both the arteries and veins, and injection of Onyx, resulting in complete devascularization of the tumor's arteriovenous network.
  • [MeSH-major] Dimethyl Sulfoxide / administration & dosage. Embolization, Therapeutic / methods. Head and Neck Neoplasms / therapy. Paraganglioma / therapy. Polyvinyls / administration & dosage

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • Hazardous Substances Data Bank. DIMETHYL SULFOXIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17988740.001).
  • [ISSN] 0150-9861
  • [Journal-full-title] Journal of neuroradiology. Journal de neuroradiologie
  • [ISO-abbreviation] J Neuroradiol
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Onyx copolymer; 0 / Polyvinyls; YOW8V9698H / Dimethyl Sulfoxide
  •  go-up   go-down


12. Candela G, Varriale S, Di Libero L, Giordano M, Maschio A, Manetta F, Borrelli V, Nunziata A, Santini L: Carcinoid of the vermiform appendix. Description of three clinical cases and review of the literature. Minerva Chir; 2006 Jun;61(3):265-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Carcinoids of the appendix represent a separate class of tumours with characteristics that vary between benign (adenomas) and malignant (carcinomas) neoplasias.
  • A recent nomenclature identifies them as diffuse neuroendocrine system (DNS) and/or, parallely, as neuroendocrine tumours (NET): the gastroenteric tract is the site of about 64.3% of carcinoids, followed by the respiratory tract with 25.3%.
  • Among the gastrointestinals, tumour of the small intestine is the one with the highest incidence with 28.5%, followed by the appendix with 4.77%, the rectum with 13.6% and the stomach with 4.6%.
  • The first case is that of a female patient in whom the primary tumour was only discovered after liver metastasis was documented.
  • Both laboratory and instrumental examinations contribute to the diagnosis of intestinal carcinoid.
  • First level instrumental examinations for the diagnosis of intestinal carcinoid are represented by CT with and without contrast medium, diagnostic endoscopy and, to better highlight the presence of locoregional metastases, scintigraphy with octreotide and PET.
  • Treatment with somatostatin, on the other hand, proved effective in controlling tumour secretion, so attenuating the inconveniences of carcinoid syndrome.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16858310.001).
  • [ISSN] 0026-4733
  • [Journal-full-title] Minerva chirurgica
  • [ISO-abbreviation] Minerva Chir
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


13. Tambo M, Fujimoto K, Miyake M, Hoshiyama F, Matsushita C, Hirao Y: Clinicopathological review of 46 primary retroperitoneal tumors. Int J Urol; 2007 Sep;14(9):785-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathological review of 46 primary retroperitoneal tumors.
  • OBJECTIVES: To clarify the clinical factors including diagnostic imaging findings that may correlate with the histopathological malignancy in primary retroperitoneal tumors.
  • METHODS: The clinical backgrounds and imaging findings of 22 benign and 24 malignant primary retroperitoneal tumors were retrospectively investigated, and the prognosis of patients with malignant retroperitoneal tumors was assessed.
  • RESULTS: There were significant correlations between the presence of symptoms and malignancy (P < 0.01), as well as between the irregularity of tumor margins and malignancy (P < 0.01).
  • On dynamic magnetic resonance imaging (MRI), 90% of malignant tumors showed early enhancement either with quick or slow washout, while 75% of benign tumors showed delayed and no enhancement (P < 0.002).
  • All malignant and benign paraganglioma showed the same early enhancement with quick washout.
  • The 2-year and 5-year cause-specific survival rates of the patients with malignant retroperitoneal tumors were 68.0% and 43.2%, respectively.
  • Malignant paraganglioma patients who could not meet complete resection needed chemotherapy for promising survival.
  • CONCLUSION: The symptoms, the irregularity of the margins, and the specific enhancement pattern on the dynamic MRI may be important predictive factors of the primary malignant retroperitoneal tumors.
  • Histological diagnosis was needed for malignant definition of paraganglioma because both benign and malignant paraganglioma showed similar clinical and imaging findings.
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Neoplasm Invasiveness. Prognosis. Retroperitoneal Space / pathology. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17760742.001).
  • [ISSN] 0919-8172
  • [Journal-full-title] International journal of urology : official journal of the Japanese Urological Association
  • [ISO-abbreviation] Int. J. Urol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


14. Krstić M, Sumarac M, Diklić A, Tatić S, Pavlović A, Tomić D, Micić D, Kendereski A, Milinić N, Petakov M: [Endoscopic ultrasonography (EUS) in preoperative localization of neuroendocrine tumors (NET) of the pancreas]. Acta Chir Iugosl; 2005;52(1):97-100
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Endoscopic ultrasonography (EUS) in preoperative localization of neuroendocrine tumors (NET) of the pancreas].
  • BACKGROUND: Preoperative localization of pancreatic neuroendocrine tumours (NET) is usually very difficult.
  • We studied the location, the size and echo-pattern of the neoplasm.
  • Six tumours were benign (75%), and two were malign (25%).
  • We localized 6 insulinomas and single pancreatic carcinoid tumour.
  • The median tumour size detected by EUS was 21mm.
  • [MeSH-major] Endosonography. Neuroendocrine Tumors / ultrasonography. Pancreatic Neoplasms / ultrasonography

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16119321.001).
  • [ISSN] 0354-950X
  • [Journal-full-title] Acta chirurgica Iugoslavica
  • [ISO-abbreviation] Acta Chir Iugosl
  • [Language] srp
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Serbia and Montenegro
  •  go-up   go-down


15. Unal M, Polat A, Pata YS, Vayisoğlu Y, Yildiz A, Ismi O: Paraganglioma of the skull base: a case report. Auris Nasus Larynx; 2007 Sep;34(3):427-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Paraganglioma of the skull base: a case report.
  • Paragangliomas are rare benign neuroendocrine tumors derived from the extra-adrenal paraganglia of the autonomic nervous system.
  • Here, we described a new case of a 75-year-old woman with paraganglioma arising in the middle and posterior cranial fossa with extended destruction of the skull base and clivus.
  • [MeSH-major] Paraganglioma / diagnosis. Skull Base Neoplasms / diagnosis
  • [MeSH-minor] Aged. Biomarkers, Tumor / analysis. Biopsy. Chromogranin A / analysis. Endoscopy. Female. Humans. Magnetic Resonance Imaging. Respiratory Insufficiency / etiology. S100 Proteins / analysis. Skull Base / pathology. Synaptophysin / analysis. Tomography, X-Ray Computed. Vocal Cord Paralysis / etiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17331688.001).
  • [ISSN] 0385-8146
  • [Journal-full-title] Auris, nasus, larynx
  • [ISO-abbreviation] Auris Nasus Larynx
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Chromogranin A; 0 / S100 Proteins; 0 / Synaptophysin
  •  go-up   go-down


16. Turley AJ, Hunter S, Stewart MJ: A cardiac paraganglioma presenting with atypical chest pain. Eur J Cardiothorac Surg; 2005 Aug;28(2):352-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A cardiac paraganglioma presenting with atypical chest pain.
  • Primary cardiac tumours are rare.
  • The majority are benign and 75% are atrial myxomas.
  • One of the more unusual benign tumours affecting the heart is a cardiac paraganglioma.
  • All investigations, haematological, biochemical, neuroendocrine tumour markers and urinary cathecholamine levels, were within normal limits.
  • Macroscopically the tumour involved the whole of the atrial septum, roof of the left atrium and extended to surround the superior vena cava, excluding total resection.
  • The feeding vessels were ligated in the hope of infarcting the remainder of the tumour.
  • To our knowledge this is the first reported case where vascular ligation has been used to control a cardiac paraganglioma.
  • [MeSH-major] Chest Pain / etiology. Heart Neoplasms / complications. Paraganglioma / complications

  • MedlinePlus Health Information. consumer health - Chest Pain.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15990328.001).
  • [ISSN] 1010-7940
  • [Journal-full-title] European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
  • [ISO-abbreviation] Eur J Cardiothorac Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


17. Ardeleanu C, Dănăilă L, Arsene D: Paraganglioma of the cerebellopontine angle. Case presentation and pathological considerations. Rom J Morphol Embryol; 2005;46(3):171-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Paraganglioma of the cerebellopontine angle. Case presentation and pathological considerations.
  • Paragangliomas (glomus tumors) arise from the extra-adrenal neuroendocrine system.
  • They are benign but locally aggressive tumors, causing bone destruction and compression related symptoms.
  • We present a case of paraganglioma of the cerebellopontine angle.
  • [MeSH-major] Cerebellar Neoplasms / pathology. Cerebellopontine Angle / pathology. Paraganglioma / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16444300.001).
  • [ISSN] 1220-0522
  • [Journal-full-title] Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie
  • [ISO-abbreviation] Rom J Morphol Embryol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Romania
  • [Chemical-registry-number] 0 / Glial Fibrillary Acidic Protein; 0 / Ki-67 Antigen
  •  go-up   go-down


18. Unger N, Serdiuk I, Sheu SY, Walz MK, Schulz S, Saeger W, Schmid KW, Mann K, Petersenn S: Immunohistochemical localization of somatostatin receptor subtypes in benign and malignant adrenal tumours. Clin Endocrinol (Oxf); 2008 Jun;68(6):850-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical localization of somatostatin receptor subtypes in benign and malignant adrenal tumours.
  • BACKGROUND: Somatostatin mediates its action through five receptor subtypes (sst1-5) that are widely distributed in various endocrine tissues and tumours.
  • In contrast to their well-established use in neuroendocrine and pituitary tumours, little is known about their potential use in adrenal tumours.
  • OBJECTIVE: We examined somatostatin receptor protein expression in adrenal tumours of various aetiologies.
  • DESIGN: Seven benign and eight malignant pheochromocytomas (PHEOs), eight aldosterone-secreting adenomas (APAs), nine cortisol-secreting adenomas (CPAs), seven nonfunctioning adrenal tumours (NFAs) and 25 adrenal carcinomas (CAs) as well as eight normal adrenal glands were investigated.
  • However, in the majority of these tumours, less than 30% of cells were positively stained.
  • All benign PHEOs were positive for sst3.
  • The majority presented with more than 60% of tumour cells stained.
  • CONCLUSIONS: Somatostatin receptor subtypes are expressed in PHEOs as well as in tumours of the adrenal cortex with tumour-specific distribution patterns.

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18031328.001).
  • [ISSN] 1365-2265
  • [Journal-full-title] Clinical endocrinology
  • [ISO-abbreviation] Clin. Endocrinol. (Oxf)
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Receptors, Somatostatin
  •  go-up   go-down


19. Druce MR, Kaltsas GA, Fraenkel M, Gross DJ, Grossman AB: Novel and evolving therapies in the treatment of malignant phaeochromocytoma: experience with the mTOR inhibitor everolimus (RAD001). Horm Metab Res; 2009 Sep;41(9):697-702
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Phaeochromocytoma and paraganglioma are rare neuroendocrine tumours (NETS).
  • They may be benign or malignant but the pathological distinction is mainly made when metastases are present.
  • Available treatments in the form of surgery, chemotherapy, and radionuclide therapy may improve symptoms and biochemical markers, but the results for the control of tumour bulk are less favourable.
  • This short review outlines the main molecular and histological features of malignant phaeochromocytoma and the difficulties in differentiating between benign and malignant disease.
  • We have used RAD001 in four patients with progressive malignant paraganglioma/phaeochromocytoma in addition to other therapies (with institutional approval for compassionate use), and evaluated the effects of this treatment.

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • MedlinePlus Health Information. consumer health - Pheochromocytoma.
  • Hazardous Substances Data Bank. SIROLIMUS .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19424940.001).
  • [ISSN] 1439-4286
  • [Journal-full-title] Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et métabolisme
  • [ISO-abbreviation] Horm. Metab. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Protein Kinase Inhibitors; 9HW64Q8G6G / Everolimus; EC 2.7.- / Protein Kinases; EC 2.7.1.1 / MTOR protein, human; EC 2.7.1.1 / TOR Serine-Threonine Kinases; W36ZG6FT64 / Sirolimus
  •  go-up   go-down


20. Klöppel G: Tumour biology and histopathology of neuroendocrine tumours. Best Pract Res Clin Endocrinol Metab; 2007 Mar;21(1):15-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumour biology and histopathology of neuroendocrine tumours.
  • The tumours of the disseminated/diffuse neuroendocrine cell system are a group of neoplasms sharing uniformly appearing cells which differ from each other in their biology, prognosis and genetics.
  • In the lung they are called carcinoid and small/large-cell neuroendocrine carcinomas.
  • In the gastroenteropancreatic compartment they are classified as well-differentiated neuroendocrine tumours or carcinomas and poorly differentiated neuroendocrine carcinomas.
  • Their clinical behaviour--ranging from benign and low-grade to high-grade malignancy--can be predicted on the basis of clinicopathological criteria.
  • [MeSH-major] Neuroendocrine Tumors / pathology
  • [MeSH-minor] Biomarkers / analysis. Biomarkers, Tumor / analysis. Carcinoma / classification. Carcinoma / diagnosis. Carcinoma / genetics. Carcinoma / pathology. Gastrointestinal Neoplasms / classification. Gastrointestinal Neoplasms / diagnosis. Gastrointestinal Neoplasms / genetics. Gastrointestinal Neoplasms / pathology. Gene Expression Profiling. Gene Expression Regulation, Neoplastic. Humans. Neurosecretory Systems / cytology. Prognosis. Respiratory Tract Neoplasms / classification. Respiratory Tract Neoplasms / diagnosis. Respiratory Tract Neoplasms / genetics. Respiratory Tract Neoplasms / pathology

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17382263.001).
  • [ISSN] 1521-690X
  • [Journal-full-title] Best practice & research. Clinical endocrinology & metabolism
  • [ISO-abbreviation] Best Pract. Res. Clin. Endocrinol. Metab.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Biomarkers, Tumor
  • [Number-of-references] 48
  •  go-up   go-down


21. Haikal F, Maceira J, Dias E, Ramos-E-Silva M: Histogenesis of Abrikossoff tumour of the oral cavity. Int J Dent Hyg; 2010 Feb;8(1):53-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Histogenesis of Abrikossoff tumour of the oral cavity.
  • BACKGROUND: Abrikossoff or granular cell tumour (GCT) is a relatively rare neoplasia, benign in most of the cases.
  • Immunohistochemical techniques suggest its origin in the Schwann cells, while more recent studies with new markers indicate an origin related to neuroendocrine cells.
  • OBJECTIVE: Contribute to the clarification of histogenesis of oral Abrikossoff tumour studying immunohistochemical marking of 11 oral Brazilian cases.
  • MATERIALS AND METHODS: Samples of tissues from the oral mucosa, tongue and lips placed in paraffin blocks, from eleven patients with a histopathological diagnosis of benign GCT were studied.
  • Less intense positivity was found in some cases, for ENE and PGP9.5, which suggests a neuroendocrine origin.
  • CONCLUSIONS: The results obtained suggest an origin from Schwann cells, but also arise the possibility of neuroendocrine origin.
  • New methods and more specific immunohistochemical markers are needed to elucidate the origin of the Abrikossoff tumour.
  • [MeSH-major] Granular Cell Tumor / pathology. Mouth Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Biomarkers, Tumor / analysis. Cell Nucleus / pathology. Cytoplasm / pathology. Female. Humans. Hyperplasia. Immunohistochemistry. Lip Neoplasms / pathology. Male. Middle Aged. Mouth Mucosa / pathology. Neuroendocrine Cells / pathology. Phosphopyruvate Hydratase / analysis. S100 Proteins / analysis. Schwann Cells / pathology. Tongue Neoplasms / pathology. Ubiquitin Thiolesterase / analysis. Vimentin / analysis. Young Adult

  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20096083.001).
  • [ISSN] 1601-5037
  • [Journal-full-title] International journal of dental hygiene
  • [ISO-abbreviation] Int J Dent Hyg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / S100 Proteins; 0 / Vimentin; EC 3.1.2.15 / UCHL1 protein, human; EC 3.1.2.15 / Ubiquitin Thiolesterase; EC 4.2.1.11 / Phosphopyruvate Hydratase
  •  go-up   go-down


22. Fuentes C, Menéndez E, Pineda J, Martínez De Esteban JP, Anda E, Goñi MJ, Bausch B, Neumann HP: The malignant potential of a succinate dehydrogenase subunit B germline mutation. J Endocrinol Invest; 2006 Apr;29(4):350-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Familial catecholamine secreting tumors have been associated with multiple endocrine neoplasia type 2, Von Hippel-Lindau disease and neurofibromatosis type 1.
  • In the last years, mutations of genes encoding subunits B, C and D of the succinate dehydrogenase have been discovered as other causes of pheochromocytomas and paragangliomas.
  • We diagnosed a malignant retroperitoneal paraganglioma in a 64-yr-old man with bone metastasis in 2001.
  • Two years later a retroperitoneal benign paraganglioma was found and resected in his 32-yr-old daughter.
  • Thus we diagnosed in this family a paraganglioma syndrome.
  • [MeSH-major] Germ-Line Mutation. Iron-Sulfur Proteins / genetics. Paraganglioma / genetics. Protein Subunits / genetics. Retroperitoneal Neoplasms / genetics. Succinate Dehydrogenase / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 2003 Jun 26;348(26):2656-68 [12826641.001]
  • [Cites] Am J Hum Genet. 2001 Dec;69(6):1186-97 [11605159.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Jun;86(6):2890-4 [11397905.001]
  • [Cites] JAMA. 2004 Aug 25;292(8):943-51 [15328326.001]
  • [Cites] Lancet. 2001 Apr 14;357(9263):1181-2 [11323050.001]
  • [Cites] Am J Hum Genet. 2001 Jul;69(1):49-54 [11404820.001]
  • [Cites] J Clin Endocrinol Metab. 2002 Sep;87(9):4101-5 [12213855.001]
  • [Cites] J Clin Endocrinol Metab. 2002 Oct;87(10):4771-4 [12364472.001]
  • [Cites] Science. 2000 Feb 4;287(5454):848-51 [10657297.001]
  • [Cites] N Engl J Med. 2002 May 9;346(19):1459-66 [12000816.001]
  • (PMID = 16699302.001).
  • [ISSN] 0391-4097
  • [Journal-full-title] Journal of endocrinological investigation
  • [ISO-abbreviation] J. Endocrinol. Invest.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Iron-Sulfur Proteins; 0 / Protein Subunits; EC 1.3.5.1 / SDHB protein, human; EC 1.3.99.1 / Succinate Dehydrogenase
  •  go-up   go-down


23. Uysal-Onganer P, Kawano Y, Caro M, Walker MM, Diez S, Darrington RS, Waxman J, Kypta RM: Wnt-11 promotes neuroendocrine-like differentiation, survival and migration of prostate cancer cells. Mol Cancer; 2010 Mar 10;9:55
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Wnt-11 promotes neuroendocrine-like differentiation, survival and migration of prostate cancer cells.
  • BACKGROUND: Wnt-11 is a secreted protein that modulates cell growth, differentiation and morphogenesis during development.
  • However, the prevalence of increased expression of Wnt-11 in patient tumours and the functions of Wnt-11 in prostate cancer cells were not known.
  • RESULTS: Wnt-11 protein levels in prostate tumours were determined by immunohistochemical analysis of prostate tumour tissue arrays.
  • Wnt-11 protein was elevated in 77/117 of tumours when compared with 27 benign prostatic hypertrophy specimens and was present in 4/4 bone metastases.
  • Androgen-depleted LNCaP prostate cancer cells form neurites and express genes associated with neuroendocrine-like differentiation (NED), a feature of prostate tumours that have a poor prognosis.
  • In contrast, Wnt-11 did not induce NSE expression in RWPE-1 cells, which are derived from benign prostate, suggesting that the role of Wnt-11 in NED is specific to prostate cancer.
  • Finally, silencing of Wnt-11 reduced PC3 cell migration and ectopic expression of Wnt-11 promoted LNCaP cell invasion.
  • CONCLUSIONS: These observations suggest that the increased level of Wnt-11 found in prostate cancer contributes to tumour progression by promoting NED, tumour cell survival and cell migration/invasion, and may provide an opportunity for novel therapy in prostate cancer.


24. Krzysztof K, Wiktor B, Tadeusz Ł, Waldemar B, Magdalena K, Janusz D: Neuroendocrine tumours--analysis of own material--a nine--year retrospective study. Hepatogastroenterology; 2010 Mar-Apr;57(98):236-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neuroendocrine tumours--analysis of own material--a nine--year retrospective study.
  • BACKGROUND/AIMS: Neuroendocrine tumours are fairly rare neoplasms that require different treatments and have various prognoses.
  • The aim of this study was to present the author's observations of the histological tumor types, occurrence and its surgical treatment.
  • METHODOLOGY: Thirty-five cases of neuroendocrine tumours were studied retrospectively in a 9-year period.
  • Ultrasonography, scintigraphy, computed tomography or magnetic resonance imaging of abdominal cavity, pelvis, thorax or neck--depend on the tumor localization--were done in every individual.
  • All cases were subjected to surgical procedure with an aim to resect the tumour completely.
  • RESULTS: In the present study were observed 6 cases of carcinoids localized in ileum, cecum and sigmoid colon, 1 case of gastrinoma in pancreatic head localization, 1 case of insulinoma localized in pancreatic tail, 1 case of vipoma localised in pancreatic head, 2 cases of nesidioblastoma and 1 case of microcystic adenoma with neuroendocrine differentiation in pancreatic tail localization and 1 case of nonspecific apudoma observed in ileum.
  • There were 6 cases of neuroendocrine tumours localized in pancreas.
  • In adrenal glands we observed 10 benign and 1 malignant pheochromocytoma (one bilateral female case with Multiple Endocrine Neoplasia type 2A).
  • CONCLUSIONS: Neuroendocrine tumours occur very rare.
  • The clinical manifestations of some neuroendocrine tumours are not specific, so it causes a lot of difficulties in early diagnosis and treatment.
  • [MeSH-major] Gastrointestinal Neoplasms / surgery. Neuroendocrine Tumors / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20583420.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


25. Ahmed Z, Aftab K, Kayani N: Ovarian primary neuroendocrine carcinoma of non-small cell type: report of an extremely rare neoplasm. J Pak Med Assoc; 2005 Feb;55(2):82-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ovarian primary neuroendocrine carcinoma of non-small cell type: report of an extremely rare neoplasm.
  • Histologic examination and immunohistochemical features gave a diagnosis of primary neuroendocrine carcinoma of non-small cell type admixed with benign mucinous cystadenoma.
  • This is a rare tumour with only eight being reported in literature.
  • [MeSH-major] Carcinoma, Neuroendocrine / pathology. Cystadenoma, Mucinous / pathology. Ovarian Neoplasms / pathology

  • Genetic Alliance. consumer health - Ovarian small cell carcinoma.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15813637.001).
  • [ISSN] 0030-9982
  • [Journal-full-title] JPMA. The Journal of the Pakistan Medical Association
  • [ISO-abbreviation] J Pak Med Assoc
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Pakistan
  •  go-up   go-down


26. Mhawech-Fauceglia P, Saxena R, Zhang S, Terracciano L, Sauter G, Chadhuri A, Herrmann FR, Penetrante R: Pax-5 immunoexpression in various types of benign and malignant tumours: a high-throughput tissue microarray analysis. J Clin Pathol; 2007 Jun;60(6):709-14
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pax-5 immunoexpression in various types of benign and malignant tumours: a high-throughput tissue microarray analysis.
  • BACKGROUND: Pax-5 belongs to the Pax gene family transcription factors that play an important role in organogenesis and in B cell ontogeny.
  • It is expressed in B cell non-Hodgkin's lymphoma (B-NHL), Hodgkin's lymphoma (HL) and neuroendocrine carcinomas.
  • However, its expression in other tumour types is not fully explored.
  • AIMS AND METHODS: To determine Pax-5 expression in other tumour types, immunohistochemistry was performed on 3758 benign and malignant tumours using multiple tumour microarrays, as well as on whole sections.
  • RESULTS: Pax-5 was expressed in 108/118 (91.5%) B-NHLs, in 60/70 (85.7%) HLs and in 0/7 T cell lymphomas.
  • In addition, Pax-5 was seen in 24/34 (70.6%) Merkel cell carcinomas, 42/53 (79.2%) small cell carcinomas, 1/164 (0.6%) breast carcinomas, 2/204 (1%) endometrial adenocarcinomas and 1/452 (0.2%) urothelial carcinoma of the bladder.
  • CONCLUSION: Despite its expression in a small subset of malignancies of epithelial origin, Pax-5 is still a good and reliable immunomarker in diagnosing B-NHL, HL and neuroendocrine carcinomas.
  • [MeSH-major] B-Cell-Specific Activator Protein / metabolism. Biomarkers, Tumor / metabolism. Neoplasms / metabolism
  • [MeSH-minor] Carcinoma, Merkel Cell / diagnosis. Carcinoma, Merkel Cell / metabolism. Carcinoma, Squamous Cell / diagnosis. Carcinoma, Squamous Cell / metabolism. Diagnosis, Differential. Hodgkin Disease / diagnosis. Hodgkin Disease / metabolism. Humans. Immunoenzyme Techniques. Lung Neoplasms / diagnosis. Lung Neoplasms / metabolism. Lymphoma, Non-Hodgkin / diagnosis. Lymphoma, Non-Hodgkin / metabolism. Neoplasm Proteins / metabolism. Protein Array Analysis / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Immunity. 2001 Jun;14(6):779-90 [11420047.001]
  • [Cites] Am J Surg Pathol. 2005 May;29(5):687-92 [15832095.001]
  • [Cites] Trends Genet. 2002 Jan;18(1):41-7 [11750700.001]
  • [Cites] Am J Surg Pathol. 2002 Oct;26(10):1343-50 [12360049.001]
  • [Cites] Int Urol Nephrol. 2002-2003;34(4):495-501 [14577491.001]
  • [Cites] Hum Pathol. 2003 Oct;34(10):994-1000 [14608532.001]
  • [Cites] Hum Pathol. 2004 Jan;35(1):122-8 [14745734.001]
  • [Cites] Carcinogenesis. 2004 Oct;25(10):1839-46 [15155532.001]
  • [Cites] Am J Clin Pathol. 2004 Nov;122(5):721-7 [15491968.001]
  • [Cites] Mech Dev. 1992 Nov;39(1-2):29-39 [1283313.001]
  • [Cites] Genomics. 1993 Dec;18(3):705-8 [7508415.001]
  • [Cites] C R Acad Sci III. 1995 Jan;318(1):57-66 [7757805.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Jun 6;92(12):5709-13 [7777574.001]
  • [Cites] Genes Dev. 1997 Feb 15;11(4):476-91 [9042861.001]
  • [Cites] J Immunol. 1997 Apr 1;158(7):3197-204 [9120274.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 May 27;94(11):5703-8 [9159136.001]
  • [Cites] Nat Med. 1998 Jul;4(7):844-7 [9662379.001]
  • [Cites] Clin Cancer Res. 1995 Feb;1(2):207-14 [9815975.001]
  • [Cites] Gen Physiol Biophys. 1998 Sep;17(3):211-24 [9834843.001]
  • [Cites] BJU Int. 1999 Jun;83(9):1039-44 [10368252.001]
  • [Cites] Nature. 1999 Oct 7;401(6753):556-62 [10524622.001]
  • [Cites] Int J Cancer. 2001 Aug 15;93(4):459-67 [11477548.001]
  • (PMID = 16837628.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / B-Cell-Specific Activator Protein; 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins; 0 / PAX5 protein, human
  • [Other-IDs] NLM/ PMC1955074
  •  go-up   go-down


27. Capolunghi B, Bertolini G, Grillo della Berta L, Tinelli N, Cascio F, Bertoletti F: Laryngeal paraganglioma: an endoscopic diode-laser-assisted surgical approach: a case report. B-ENT; 2005;1(2):97-100
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laryngeal paraganglioma: an endoscopic diode-laser-assisted surgical approach: a case report.
  • Laryngeal paraganglioma is a rare vascular neuroendocrine benign tumour.
  • Computed tomography scans and angiography are also useful in making the diagnosis of paraganglioma before surgical intervention.
  • A case of a large supraglottic paraganglioma is described.
  • Complete excision of the tumour was achieved using microlaryngoscopical-laser surgical resection.
  • The effectiveness of this conservative endoscopic surgical procedure compared to the external approaches is discussed and it can be concluded that the endoscopic diode-laser resection of even extended laryngeal paraganglioma provides a good operative field and is a safe and effective technique.
  • [MeSH-major] Laryngeal Neoplasms / surgery. Laser Therapy / methods. Paraganglioma / surgery

  • Hazardous Substances Data Bank. Carbon dioxide .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16044742.001).
  • [ISSN] 1781-782X
  • [Journal-full-title] B-ENT
  • [ISO-abbreviation] B-ENT
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Belgium
  • [Chemical-registry-number] 142M471B3J / Carbon Dioxide
  •  go-up   go-down


28. Dajbog E, Lefter LP, Scripcariu V, Ferariu D, Dragomir C: Diagnostic features of benign pancreatic insulinomas. An analysis of three cases. J Gastrointestin Liver Dis; 2006 Mar;15(1):61-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnostic features of benign pancreatic insulinomas. An analysis of three cases.
  • Insulinoma is a neuroendocrine tumour deriving mainly from the pancreatic islet cells that produces excessive amounts of insulin.
  • We present the case reports of three patients with benign pancreatic insulinoma.
  • Their performances for the effectiveness in detecting and localizing benign insulinoma were compared.
  • [MeSH-major] Insulinoma / diagnosis. Pancreatic Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16680235.001).
  • [ISSN] 1841-8724
  • [Journal-full-title] Journal of gastrointestinal and liver diseases : JGLD
  • [ISO-abbreviation] J Gastrointestin Liver Dis
  • [Language] eng
  • [Publication-type] Case Reports; Comparative Study; Journal Article
  • [Publication-country] Romania
  •  go-up   go-down


29. Polikarpova SB, Lyubimova NV, Smirnova EA, Britvin TA, Ogereliev AS, Davidov MI: Serum angiogenic factors in patients with neuroendocrine tumors of abdominal organs. Bull Exp Biol Med; 2009 Oct;148(4):634-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serum angiogenic factors in patients with neuroendocrine tumors of abdominal organs.
  • The initial (before treatment) levels of VEGF, endostatin, and tumor necrosis factor-beta (TNF-beta) were measured in the sera of 20 patients with malignant and benign neuroendocrine tumors of the abdominal organs and 25 healthy controls.
  • The initial levels of VEGF, endostatin, and TNF-beta in the total group of patients with neuroendocrine tumors of abdominal organs did not differ from the control.
  • A significant difference was detected between the mean serum concentrations of endostatin in patients with benign and malignant neuroendocrine tumors: 64.1+/-14.7 and 107.8+/-14.1 ng/ml, respectively (p=0.043).
  • A direct correlation between endostatin, TNF-beta concentrations and maximum size of the primary tumor was detected in patients with malignant neuroendocrine tumors.
  • Direct correlations between the initial levels of VEGF and endostatin and an inverse correlation between VEGF and TNF-beta concentrations were detected in patients with benign neuroendocrine tumors.
  • [MeSH-major] Abdominal Neoplasms. Endostatins / blood. Lymphotoxin-alpha / blood. Neuroendocrine Tumors. Vascular Endothelial Growth Factor A / blood

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20396759.001).
  • [ISSN] 1573-8221
  • [Journal-full-title] Bulletin of experimental biology and medicine
  • [ISO-abbreviation] Bull. Exp. Biol. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Endostatins; 0 / Lymphotoxin-alpha; 0 / Vascular Endothelial Growth Factor A
  •  go-up   go-down


30. Chetty R: Requiem for the term 'carcinoid tumour' in the gastrointestinal tract? Can J Gastroenterol; 2008 Apr;22(4):357-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Requiem for the term 'carcinoid tumour' in the gastrointestinal tract?
  • Use of the term 'carcinoid tumour' to describe a unique type of tumour in the gastroenteropancreatic system is endemic in the medical literature and in daily clinical and pathological parlance.
  • However, it is a somewhat misleading moniker because a spectrum of histopathological changes and hence, biological outcomes may occur in these tumours.
  • The World Health Organization classification scheme recommends the use of the terms neuroendocrine tumours or carcinomas, which may be stratified as well-differentiated neuroendocrine tumours with benign or uncertain behaviour, well-differentiated tumours with low-grade neuroendocrine carcinoma behaviour and high-grade neuroendocrine carcinomas.
  • In addition, a recently suggested tumour-node-metastasis scheme has been proposed and awaits clinical validation and acceptance.
  • Thus, the term 'carcinoid' has served its purpose well, but its use should be phased out in favour of 'neuroendocrine tumour' or 'neuroendocrine carcinoma'.
  • [MeSH-major] Carcinoid Tumor / classification. Gastrointestinal Neoplasms / classification. Terminology as Topic

  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann N Y Acad Sci. 2004 Apr;1014:13-27 [15153416.001]
  • [Cites] Digestion. 1994;55 Suppl 3:3-10 [7698535.001]
  • [Cites] Hum Pathol. 2004 Dec;35(12):1440-51 [15619202.001]
  • [Cites] Neuroendocrinology. 2004;80(4):244-51 [15627802.001]
  • [Cites] Virchows Arch. 2007 Oct;451(4):757-62 [17674042.001]
  • [Cites] Endocr Relat Cancer. 2005 Dec;12(4):1083-92 [16322345.001]
  • [Cites] Anticancer Res. 2005 Nov-Dec;25(6C):4463-9 [16334127.001]
  • [Cites] Ann Oncol. 2006 Mar;17(3):461-6 [16364959.001]
  • [Cites] Virchows Arch. 2006 Oct;449(4):395-401 [16967267.001]
  • [Cites] Ann Oncol. 2005 Aug;16(8):1374-80 [15939719.001]
  • (PMID = 18414708.001).
  • [ISSN] 0835-7900
  • [Journal-full-title] Canadian journal of gastroenterology = Journal canadien de gastroenterologie
  • [ISO-abbreviation] Can. J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Canada
  • [Other-IDs] NLM/ PMC2662891
  •  go-up   go-down


31. Gourgiotis S, Moustafellos P, Zavos A, Stratopoulos C, Vericouki C, Hadjiyannakis E: Localisation and surgical treatment of insulinomas. Int J Clin Pract; 2007 Apr;61(4):558-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Most insulinomas are solitary, benign and functional neuroendocrine pancreatic tumours which give rise to manifold symptoms.
  • It was the aim of this study to analyse and evaluate our group of patients with regard to preoperative tumour localisation and overall surgical results.
  • Twelve patients with a biochemical diagnosis of organic hyperinsulinism were surgically treated.
  • Diagnosis was made with the combination of magnetic resonance imaging, computed tomography, selective angiography and intraoperative portal vein sampling.
  • In five patients, the tumour was enucleated, in three patients Whipple procedure was performed; while three patients underwent left pancreatectomy with spleen preserving in two cases.
  • Accurate diagnosis, preoperative localisation and diligent surgical exploration by experienced surgeons are the key to a successful outcome in patients with insulinomas.

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17394431.001).
  • [ISSN] 1368-5031
  • [Journal-full-title] International journal of clinical practice
  • [ISO-abbreviation] Int. J. Clin. Pract.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] England
  •  go-up   go-down


32. Righi L, Volante M, Rapa I, Scagliotti GV, Papotti M: Neuro-endocrine tumours of the lung. A review of relevant pathological and molecular data. Virchows Arch; 2007 Aug;451 Suppl 1:S51-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neuro-endocrine tumours of the lung. A review of relevant pathological and molecular data.
  • Neuroendocrine (NE) tumours of the lung include pure and mixed forms.
  • In the former group, a continuum of lesions is recognised ranging from benign typical carcinoids to atypical carcinoids (having a low-grade behaviour, although often associated with regional and distant metastases), to the highly aggressive poorly differentiated carcinomas of the small and large cell types.
  • In the mixed tumour group, the NE component is extensively represented in association with any of the non-small cell carcinoma subtypes (so-called combined carcinomas), or the NE component is restricted to a cell population scattered among adenocarcinoma cells (or more rarely within squamous or large cell carcinomas).
  • The molecular profile of NE tumours has been widely investigated to identify features helpful for the diagnosis, prognosis and even therapy for this special lung tumour category.
  • Specific chromosomal alterations, oncogene mutations and cell cycle molecule disregulation has been documented in NE tumours of the lung, as well as the expression of specific receptors or enzymes implicated in the response to biotherapies or to chemotherapeutic agents.
  • The "molecular classification" of NE tumours should be integrated to morphology, for a better definition of the different histological types and a more appropriate selection of the therapeutic strategy.
  • [MeSH-major] Lung Neoplasms / diagnosis. Neuroendocrine Tumors / diagnosis
  • [MeSH-minor] Diagnosis, Differential. Humans

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 1998 Oct;22(10):1267-76 [9777989.001]
  • [Cites] Lab Invest. 1983 Nov;49(5):519-37 [6138458.001]
  • [Cites] Am J Surg Pathol. 2006 Aug;30(8):945-53 [16861964.001]
  • [Cites] J Pathol. 1998 Oct;186(2):151-6 [9924430.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Nov 20;98(24):13790-5 [11707567.001]
  • [Cites] Brain Pathol. 2000 Jul;10(3):395-401 [10885658.001]
  • [Cites] Pathol Int. 2006 Aug;56(8):434-9 [16872437.001]
  • [Cites] J Thorac Oncol. 2015 Sep;10 (9):1240-1242 [26291007.001]
  • [Cites] Int J Surg Pathol. 2000 Oct;8(4):317-322 [11494008.001]
  • [Cites] J Clin Oncol. 1989 Nov;7(11):1614-20 [2553880.001]
  • [Cites] J Clin Invest. 1990 Sep;86(3):838-44 [2394833.001]
  • [Cites] Oncogene. 2007 Oct 18;26(48):6927-36 [17471231.001]
  • [Cites] Cancer Res. 2005 Dec 1;65(23):10680-5 [16322211.001]
  • [Cites] Thorax. 1995 May;50(5):551-4 [7541167.001]
  • [Cites] Lancet. 2004 Mar 6;363(9411):775-81 [15016488.001]
  • [Cites] Oncogene. 2002 Oct 7;21(45):6908-14 [12362273.001]
  • [Cites] Cancer. 1996 Apr 1;77(7):1284-91 [8608504.001]
  • [Cites] J Biol Chem. 1980 Aug 10;255(15):7386-90 [7391086.001]
  • [Cites] Cancer Biol Ther. 2002 Jan-Feb;1(1):65-9 [12170765.001]
  • [Cites] Hum Pathol. 2004 Sep;35(9):1148-55 [15343518.001]
  • [Cites] Hum Pathol. 2002 Feb;33(2):175-82 [11957142.001]
  • [Cites] Cancer Res. 2002 Jul 15;62(14):3971-9 [12124329.001]
  • [Cites] Cancer Res. 1999 Oct 15;59(20):5119-22 [10537285.001]
  • [Cites] Cancer Res. 2005 Sep 15;65(18):8423-32 [16166321.001]
  • [Cites] Int J Cancer. 2007 May 1;120(9):1835-41 [17311257.001]
  • [Cites] Oncogene. 1998 Jul 30;17 (4):475-9 [9696041.001]
  • [Cites] Cancer. 2005 Mar 15;103(6):1154-64 [15712207.001]
  • [Cites] Histopathology. 2005 Feb;46(2):195-201 [15693892.001]
  • [Cites] Hum Pathol. 2004 Oct;35(10):1196-209 [15492986.001]
  • [Cites] J Thorac Cardiovasc Surg. 1972 Sep;64(3):413-21 [5054879.001]
  • [Cites] Br J Cancer. 2004 Mar 22;90(6):1222-9 [15026805.001]
  • [Cites] Cancer. 2001 Jun 1;91(11):2104-9 [11391591.001]
  • [Cites] Lab Invest. 1988 Jul;59(1):5-24 [2839735.001]
  • [Cites] Am J Surg Pathol. 1995 Jun;19(6):653-8 [7755151.001]
  • [Cites] Endocr Rev. 2003 Aug;24(4):389-427 [12920149.001]
  • [Cites] Histopathology. 1990 Oct;17(4):353-8 [2124206.001]
  • [Cites] Expert Opin Investig Drugs. 2005 Mar;14(3):313-28 [15833062.001]
  • [Cites] Neuroendocrinology. 2007;85(1):54-60 [17310129.001]
  • [Cites] Q J Nucl Med Mol Imaging. 2006 Dec;50(4):272-87 [17043625.001]
  • [Cites] Mod Pathol. 2004 Feb;17(2):222-9 [14657947.001]
  • [Cites] Endocr Relat Cancer. 2005 Mar;12(1):109-17 [15788643.001]
  • [Cites] Am J Pathol. 1998 Jul;153(1):233-45 [9665484.001]
  • [Cites] J Biol Chem. 1962 Dec;237:3811-4 [13959775.001]
  • [Cites] Cancer Res. 1984 Sep;44(9):4144-50 [6744325.001]
  • [Cites] Pediatr Pathol. 1993 Mar-Apr;13(2):165-80 [8464778.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2001 Sep;9(3):229-33 [11556750.001]
  • [Cites] Jpn J Clin Oncol. 2007 Jan;37(1):16-22 [17060405.001]
  • [Cites] J Clin Oncol. 2006 Jan 1;24(1):70-6 [16382115.001]
  • [Cites] Am J Surg Pathol. 1991 Jun;15(6):529-53 [1709558.001]
  • [Cites] Virchows Arch. 2001 Dec;439(6):787-97 [11787852.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Nov 20;98(24):13784-9 [11707590.001]
  • [Cites] Cancer. 2003 May 15;97(10):2487-97 [12733148.001]
  • [Cites] Cancer. 1999 Feb 1;85(3):600-7 [10091733.001]
  • [Cites] Oncol Rep. 2006 Mar;15(3):557-64 [16465412.001]
  • [Cites] Mod Pathol. 2004 Oct;17(10):1259-67 [15154011.001]
  • [Cites] Lung Cancer. 2006 Nov;54(2):155-62 [16938365.001]
  • [Cites] Clin Cancer Res. 2005 Apr 15;11(8):2832-9 [15837730.001]
  • [Cites] Diagn Mol Pathol. 2000 Mar;9(1):47-57 [10718213.001]
  • [Cites] J Histochem Cytochem. 2002 Aug;50(8):1013-21 [12133904.001]
  • [Cites] Hum Pathol. 1998 Mar;29(3):272-9 [9496831.001]
  • [Cites] Oncogene. 2001 Mar 29;20(14):1678-87 [11313916.001]
  • (PMID = 17684766.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Germany
  • [Number-of-references] 63
  •  go-up   go-down


33. Stutchfield BM, Joseph S, Duckworth AD, Garden OJ, Parks RW: Distal pancreatectomy: what is the standard for laparoscopic surgery? HPB (Oxford); 2009 May;11(3):210-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND/AIMS: Distal pancreatectomy (DP) is performed for a range of benign and malignant lesions.
  • Accurate pre-operative diagnosis can be unreliable and morbidity remains high.
  • RESULTS: Sixty-five patients (mean age 49.9 years) had final diagnoses of chronic pancreatitis +/- pseudocyst (n= 22), benign cystadenoma (n= 15), neuroendocrine tumour (n= 8), primary pancreatic carcinoma (n= 6) and 14 other conditions.
  • DP performed for presumed cystic neoplasm (n= 24) revealed a correct pre-operative diagnosis in 71% of patients.
  • Histological examination confirmed that 59% of resected cystic tumours were either malignant or had malignant potential.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] HPB (Oxford). 2008;10(1):38-42 [18695757.001]
  • [Cites] Dig Surg. 2004;21(1):54-9 [14707394.001]
  • [Cites] Ann Surg. 2007 Jul;246(1):77-82 [17592294.001]
  • [Cites] Ann Surg. 2007 Mar;245(3):443-51 [17435552.001]
  • [Cites] Ann Surg. 2006 Dec;244(6):931-7; discussion 937-9 [17122618.001]
  • [Cites] ANZ J Surg. 2006 May;76(5):325-31 [16768691.001]
  • [Cites] Arch Surg. 2003 Apr;138(4):427-3; discussion 433-4 [12686529.001]
  • [Cites] Br J Surg. 2003 Feb;90(2):190-6 [12555295.001]
  • [Cites] Ann Surg. 2002 Nov;236(5):612-8 [12409667.001]
  • [Cites] J Gastrointest Surg. 2000 Nov-Dec;4(6):567-79 [11307091.001]
  • [Cites] Am J Surg. 2006 Feb;191(2):198-200 [16442945.001]
  • [Cites] Surgery. 2005 Oct;138(4):672-9; discussion 679-80 [16269296.001]
  • [Cites] Br J Surg. 2005 Sep;92(9):1059-67 [16044410.001]
  • [Cites] Surgery. 2005 Jul;138(1):8-13 [16003309.001]
  • [Cites] J Gastrointest Surg. 2005 Jul-Aug;9(6):837-42 [15985241.001]
  • [Cites] Surgery. 2005 Jun;137(6):597-605 [15962401.001]
  • [Cites] Br J Surg. 2005 May;92(5):539-46 [15852419.001]
  • [Cites] Ann Surg. 1999 May;229(5):693-8; discussion 698-700 [10235528.001]
  • [Cites] Am J Surg. 2004 Jun;187(6):705-12 [15191862.001]
  • [Cites] Gastroenterology. 2004 May;126(5):1330-6 [15131794.001]
  • [Cites] World J Surg. 2008 May;32(5):904-17 [18264824.001]
  • (PMID = 19590649.001).
  • [ISSN] 1365-182X
  • [Journal-full-title] HPB : the official journal of the International Hepato Pancreato Biliary Association
  • [ISO-abbreviation] HPB (Oxford)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2697890
  • [Keywords] NOTNLM ; distal pancreatectomy / laparoscopic / postoperative pancreatic fistula
  •  go-up   go-down


34. Moriya T, Kozuka Y, Kanomata N, Tse GM, Tan PH: The role of immunohistochemistry in the differential diagnosis of breast lesions. Pathology; 2009 Jan;41(1):68-76
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of immunohistochemistry in the differential diagnosis of breast lesions.
  • Immunohistochemistry may be helpful in the diagnosis of various breast lesions.
  • It can be used to assist in distinguishing benign and malignant conditions, or to clarify the histological subtype of invasive carcinomas.
  • They are employed to verify myoepithelial cell lining in intraductal papillary lesions, or to recognise peripheral myoepithelial cells for non-invasive carcinoma, although their staining results are not always excellent.
  • High molecular weight cytokeratins (CK5/6, CK14, 34betaE12) typically show a mosaic-like pattern of expression in benign papillary/hyperplastic lesions, and are mostly negative in ductal in situ carcinoma, but some exceptions exist.
  • Neuroendocrine differentiation (confirmed by anti-chromogranin A or synaptophysin) suggests malignancy in solid and papillary intraductal epithelial proliferations.
  • Negative E-cadherin staining is used for making confirmative diagnosis of lobular carcinoma, with a specificity and sensitivity of approximately 90%.
  • Cytokeratins, especially the antibody 34betaE12, are of value to differentiate spindle cell carcinoma from phyllodes tumour.
  • Nevertheless, for accurate diagnosis, it is essential to correlate the immmunohistochemical staining results with the histological findings.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Breast Neoplasms / diagnosis. Breast Neoplasms / metabolism. Immunohistochemistry / methods
  • [MeSH-minor] Carcinoma, Intraductal, Noninfiltrating / diagnosis. Carcinoma, Intraductal, Noninfiltrating / metabolism. Carcinoma, Intraductal, Noninfiltrating / pathology. Carcinoma, Lobular / diagnosis. Carcinoma, Lobular / metabolism. Carcinoma, Lobular / pathology. Carcinoma, Papillary / diagnosis. Carcinoma, Papillary / metabolism. Carcinoma, Papillary / pathology. Diagnosis, Differential. Female. Humans. Myoepithelioma / diagnosis. Myoepithelioma / metabolism. Myoepithelioma / pathology


35. Sandmann M, Fähndrich M, Lorenzen J, Heike M: [Gangliocytic paraganglioma--a rare cause of an upper gastrointestinal bleeding]. Z Gastroenterol; 2010 Nov;48(11):1297-300
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Gangliocytic paraganglioma--a rare cause of an upper gastrointestinal bleeding].
  • [Transliterated title] Gangliozytisches Paragangliom--eine seltene Ursache für eine obere gastrointestinale Blutung.
  • INTRODUCTION: Gangliocytic paraganglioma is a rare tumour, occurring nearly exclusively in the descending part of the duodenum.
  • It is regarded as a mostly benign tumour but of unknown malignant potential, which rarely metastasises to local lymph nodes or distantly.
  • Oesophagogastroduodenoscopy showed an ulcerous periampullary tumour in the duodenum with a diameter of approximately 5 cm.
  • Endoscopic ultrasonography showed no evidence of tumour infiltration of the tunica muscularis and of locoregional lymph node metastasis.
  • Therefore, complete endoscopic resection of the tumour was achieved after ligating the tumour base by an endoloop using a dual channel endoscope.
  • In a second step, the tumour base was resected by endoscopic submucosal dissection (ESD) and revealed no residual tumour.
  • The histological evaluation showed a gangliocytic paranganglioma consisting of three specific cell types: epithelioid cells arranged in typical carcinoid-like patterns, spindle cells wrapped around nests of epithelioid cells and ganglion cells.
  • All cell types expressed neuron-specific enolase (NSE) as a neuroendocrine marker.
  • Synaptophysine was expressed mainly by the epithelioid and ganglion cells while the protein S 100 was expressed mainly by the spindle cells, which surround the epithelioid cell nests as a sustentacular network.
  • [MeSH-major] Duodenal Neoplasms / complications. Duodenal Neoplasms / pathology. Duodenum / pathology. Gastrointestinal Hemorrhage / etiology. Gastrointestinal Hemorrhage / pathology. Paraganglioma / complications. Paraganglioma / pathology

  • MedlinePlus Health Information. consumer health - Gastrointestinal Bleeding.
  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © Georg Thieme Verlag KG Stuttgart · New York.
  • (PMID = 21043008.001).
  • [ISSN] 1439-7803
  • [Journal-full-title] Zeitschrift für Gastroenterologie
  • [ISO-abbreviation] Z Gastroenterol
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


36. Tracey JY, Moossa AR: Unusual tumours of the pancreas. Surgeon; 2009 Aug;7(4):216-23
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Unusual tumours of the pancreas.
  • We review a rarer group of pancreatic lesions and discuss their pathogenesis, diagnosis and treatment.
  • A tumour specific selective surgical approach is recommended.
  • The outcome is dependent on the tumour histology and the biological behaviour.
  • The degree of malignancy is variable and ranges across benign, borderline and malignant entities.
  • Though the list is long they include neuroendocrine tumours, cystic tumours, primary pancreatic lymphoma, solid pseudopapillary tumours, connective tissue tumours, metastatic lesions to the pancreas and many others.

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19736888.001).
  • [ISSN] 1479-666X
  • [Journal-full-title] The surgeon : journal of the Royal Colleges of Surgeons of Edinburgh and Ireland
  • [ISO-abbreviation] Surgeon
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Scotland
  • [Number-of-references] 50
  •  go-up   go-down


37. Breysem L, Kersemans P, Vanbeckevoort D, Ectors N, Smet MH: Nonfunctioning neuroendocrine tumor of the pancreas in an 8-year-old girl. JBR-BTR; 2007 Nov-Dec;90(6):528-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nonfunctioning neuroendocrine tumor of the pancreas in an 8-year-old girl.
  • We report a case of a nonfunctioning neuroendocrine pancreatic tumor in the pediatric age group.
  • After surgical resection, the diagnosis of a hormonally inactive benign neuroendocrine tumor is histologically diagnosed.
  • [MeSH-major] Neuroendocrine Tumors / diagnosis. Pancreatic Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Pancreatic islet cell tumors.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18376771.001).
  • [ISSN] 0302-7430
  • [Journal-full-title] JBR-BTR : organe de la Société royale belge de radiologie (SRBR) = orgaan van de Koninklijke Belgische Vereniging voor Radiologie (KBVR)
  • [ISO-abbreviation] JBR-BTR
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Belgium
  • [Chemical-registry-number] 0 / Contrast Media
  •  go-up   go-down


38. Shanks JH, Iczkowski KA: Divergent differentiation in urothelial carcinoma and other bladder cancer subtypes with selected mimics. Histopathology; 2009 Jun;54(7):885-900
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A variety of unusual architectural patterns of urothelial carcinoma, such as the nested, microcystic and inverted variants, can be mistaken for reactive processes or benign tumours.
  • Others such as the micropapillary, plasmacytoid and discohesive variants, can mimic metastatic tumour from other sites.
  • In addition, urothelial carcinoma has a propensity to demonstrate divergent differentiation with glandular, squamous, small cell neuroendocrine, lymphoepithelioma-like, sarcomatoid or other elements.
  • Sarcomatoid carcinoma and its differential diagnosis with other spindle cell lesions of urinary tract will be covered in a separate review.
  • [MeSH-minor] Adenocarcinoma, Clear Cell / diagnosis. Adenocarcinoma, Clear Cell / pathology. Adenoma / diagnosis. Adenoma / pathology. Carcinoma, Squamous Cell / diagnosis. Carcinoma, Squamous Cell / pathology. Carcinoma, Transitional Cell / diagnosis. Carcinoma, Transitional Cell / pathology. Cell Differentiation. Cystitis / diagnosis. Cystitis / pathology. Diagnosis, Differential. Giant Cell Tumors / diagnosis. Giant Cell Tumors / pathology. Humans. Neoplasm Metastasis / diagnosis. Neoplasm Metastasis / pathology. Neoplasms, Squamous Cell / diagnosis. Neoplasms, Squamous Cell / pathology. Neuroendocrine Tumors / diagnosis. Neuroendocrine Tumors / pathology. Radiation Injuries / diagnosis. Radiation Injuries / pathology. Urothelium / pathology

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19178589.001).
  • [ISSN] 1365-2559
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 152
  •  go-up   go-down


39. Cathenis K, Hamerlijnck R, Vermassen F, Van Nooten G, Muysoms F: Concomitant cardiac surgery and pulmonary resection. Acta Chir Belg; 2009 May-Jun;109(3):306-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Histology of the pulmonary lesion was squamous cell carcinoma in 14 patients (52%), adenocarcinoma in 10 (37%), large cell neuroendocrine tumour in 1 (3%) and typical carcinoid in 1 (3%).
  • A benign lesion was found in 1 patient (3%).


40. Koljonen V, Jahkola T, Tukiainen E, Granroth G, Haglund C, Böhling T: Tenascin-C in primary Merkel cell carcinoma. J Clin Pathol; 2005 Mar;58(3):297-300
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tenascin-C in primary Merkel cell carcinoma.
  • BACKGROUND/AIMS: Merkel cell carcinoma (MCC) is a rare malignant cutaneous neuroendocrine tumour that mostly affects the elderly.
  • It shows rapid progression of the primary tumour, together with a vertical growth pattern into the underlying subcutaneous tissue.
  • Tenascin-C (Tn-C) is a large extracellular matrix glycoprotein that is expressed in various benign and malignant processes.
  • In previous studies, Tn-C expression correlated with prognosis in tumours of different origin.
  • Staining was mainly seen in the invasion borders and within the connective tissue septae inside the tumours.
  • The expression of Tn-C correlated significantly with large tumour size.
  • There was also frequent expression of Tn-C in primary tumours with metastatic dissemination.
  • CONCLUSIONS: Tn-C expression seems to increase with tumour size and malignant behaviour.
  • Expression was slightly enhanced in tumours with high proliferative indices.
  • Expression is seen mainly in areas of invasive growth and, in this respect, resembles that of other invasive tumours.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Carcinoma, Merkel Cell / metabolism. Neoplasm Proteins / metabolism. Skin Neoplasms / metabolism. Tenascin / metabolism
  • [MeSH-minor] Aged. Aged, 80 and over. Cell Division. Female. Humans. Immunoenzyme Techniques. Male. Middle Aged. Neoplasm Invasiveness. Prognosis

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hum Pathol. 2000 Jan;31(1):58-62 [10665914.001]
  • [Cites] Nat Med. 1999 Jun;5(6):662-8 [10371505.001]
  • [Cites] Int J Cancer. 2002 Mar 20;98(3):362-9 [11920587.001]
  • [Cites] Forensic Sci Int. 2002 Apr 18;126(2):118-22 [12084487.001]
  • [Cites] Neurosurgery. 2002 Jul;51(1):183-92; discussion 192-3 [12182416.001]
  • [Cites] Oncology. 2003;64(3):245-50 [12697965.001]
  • [Cites] Anticancer Res. 2003 May-Jun;23(3C):3051-6 [12926160.001]
  • [Cites] Eur J Surg Oncol. 2003 Sep;29(7):607-10 [12943628.001]
  • [Cites] Int J Cancer. 2004 Jan 1;108(1):31-40 [14618612.001]
  • [Cites] APMIS. 2004 Jan;112(1):39-44 [14961973.001]
  • [Cites] Anticancer Res. 2003 Nov-Dec;23(6C):4587-91 [14981900.001]
  • [Cites] Cancer Res. 1983 Jun;43(6):2796-805 [6342760.001]
  • [Cites] Sci Am. 1986 Jun;254(6):42-51 [3010451.001]
  • [Cites] Dev Biol. 1988 Aug;128(2):245-55 [2456233.001]
  • [Cites] Annu Rev Cell Biol. 1989;5:71-92 [2480799.001]
  • [Cites] J Am Acad Dermatol. 1990 Aug;23(2 Pt 1):254-6 [2170468.001]
  • [Cites] Br J Dermatol. 1991 Jan;124(1):13-20 [1704250.001]
  • [Cites] Int J Cancer. 1991 Apr 1;47(6):811-6 [1707033.001]
  • [Cites] Am J Pathol. 1991 Nov;139(5):1143-50 [1719820.001]
  • [Cites] Invasion Metastasis. 1991;11(6):325-31 [1726610.001]
  • [Cites] Development. 1993 Apr;117(4):1183-98 [8404525.001]
  • [Cites] Perspect Dev Neurobiol. 1994;2(1):111-16 [7530137.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1995 Jan 15;31(2):315-23 [7836085.001]
  • [Cites] Methods Enzymol. 1994;245:52-61 [7539094.001]
  • [Cites] Int Arch Allergy Immunol. 1995 Aug;107(4):484-90 [7620364.001]
  • [Cites] Int J Cancer. 1996 Dec 20;69(6):445-7 [8980244.001]
  • [Cites] Matrix Biol. 1998 Aug;17(4):305-16 [9749946.001]
  • [Cites] Clin Cancer Res. 1995 Sep;1(9):1035-41 [9816077.001]
  • [Cites] Br J Cancer. 1998 Dec;78(11):1507-13 [9836485.001]
  • [Cites] Eur J Cancer. 1998 Oct;34(11):1687-92 [9893653.001]
  • [Cites] Am J Dermatopathol. 1999 Feb;21(1):16-20 [10027519.001]
  • [Cites] Gynecol Oncol. 1999 Jun;73(3):415-21 [10366470.001]
  • [Cites] Surg Neurol. 2000 Sep;54(3):235-40 [11118570.001]
  • (PMID = 15735164.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins; 0 / Tenascin
  • [Other-IDs] NLM/ PMC1770604
  •  go-up   go-down


41. Angouridakis N, Hytiroglou P, Markou K, Bouzakis A, Vital V: Middle ear adenoma/carcinoid tumour: a case report and review of the literature. Rev Laryngol Otol Rhinol (Bord); 2009;130(3):199-202
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Middle ear adenoma/carcinoid tumour: a case report and review of the literature.
  • Middle ear adenoma, a rare benign tumour with glandular and neuroendocrine differentiation, originates from the epithelial lining of the middle ear.
  • Histological examination revealed tumour cells forming gland-like and cribriform structures, as well as compact groups.
  • On immunohistochemical staining, the tumour cells were positive for epithelial (cytokeratins, epithelial membrane antigen) and neuroendocrine (neuron specific enolase, synaptophysin, chromogranin and pancreatic polypeptide) markers.
  • CONCLUSION: Middle ear adenoma is a benign tumour that is treated by complete surgical removal.
  • The immunohistochemical staining of the present case supports the suggestion that this tumour is best described by the term neuroendocrine adenoma of the middle ear.
  • [MeSH-major] Adenoma. Carcinoid Tumor. Ear Neoplasms. Ear, Middle

  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • The Weizmann Institute of Science GeneCards and MalaCards databases. gene/protein/disease-specific - MalaCards for middle ear adenoma .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20345079.001).
  • [ISSN] 0035-1334
  • [Journal-full-title] Revue de laryngologie - otologie - rhinologie
  • [ISO-abbreviation] Rev Laryngol Otol Rhinol (Bord)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 17
  •  go-up   go-down


42. Cadden IS, Atkinson AB, Johnston BT, Pogue K, Connolly R, McCance D, Ardill JE, Russell CF, McGinty A: Cyclooxygenase-2 expression correlates with phaeochromocytoma malignancy: evidence for a Bcl-2-dependent mechanism. Histopathology; 2007 Dec;51(6):743-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AIMS: Phaeochromocytomas are rare but potentially life-threatening neuroendocrine tumours of the adrenal medulla or sympathetic nervous system ganglia.
  • There are no histological features which reliably differentiate benign from malignant phaeochromocytomas.
  • METHODS AND RESULTS: COX-2 and Bcl-2 expression were examined immunohistochemically in tissue from 41 sporadic phaeochromocytoma patients followed up for a minimum of 5 years after diagnosis.
  • There was a statistically significant association between COX-2 histoscore (intensity x proportion) and the development of tumour recurrence or metastases (P = 0.006).
  • A significant relationship was observed between coexpression of COX-2 and Bcl-2 in the primary tumour and the presence of recurrent disease (P = 0.034).
  • A highly significant association was observed between (i) tumour-associated expression of these two oncoproteins (P = 0.001) and (ii) COX-2 histoscore and the presence of Bcl-2 expression (P = 0.002).
  • CONCLUSIONS: COX-2 and Bcl-2 may promote phaeochromocytoma malignancy, and these oncoproteins may be valuable surrogate markers of an aggressive tumour phenotype.
  • [MeSH-major] Adrenal Gland Neoplasms / metabolism. Biomarkers, Tumor / analysis. Cyclooxygenase 2 / biosynthesis. Pheochromocytoma / metabolism. Proto-Oncogene Proteins c-bcl-2 / biosynthesis
  • [MeSH-minor] Adolescent. Adult. Aged. Female. Humans. Immunohistochemistry. Kaplan-Meier Estimate. Male. Middle Aged. Neoplasm Recurrence, Local

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • MedlinePlus Health Information. consumer health - Pheochromocytoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17916073.001).
  • [ISSN] 0309-0167
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Proto-Oncogene Proteins c-bcl-2; EC 1.14.99.1 / Cyclooxygenase 2
  •  go-up   go-down


43. Cascini GL, Cuccurullo V, Mansi L: The non tumour uptake of (111)In-octreotide creates new clinical indications in benign diseases, but also in oncology. Q J Nucl Med Mol Imaging; 2010 Feb;54(1):24-36
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The non tumour uptake of (111)In-octreotide creates new clinical indications in benign diseases, but also in oncology.
  • The main field of clinical applications is in neuroendocrine tumours (NET), starting by the demonstration of SS receptors (SSR) on the majority of NET, particularly on gastroenteropancreatic (GEP) tumours.
  • Because of this uptake clinical indications can be found also in active benign diseases, as Grave's ophthalmopathy, rheumatoid arthritis, histiocitosis, sarcoidosis, idiopatic pulmonary fibrosis.
  • Moreover, these cells can also determine the OCT in vivo uptake in tumours non expressing in vitro SSR, as non-snall cell lung cancer (NSCLC).
  • Because of a different kinetic respect to SCLC a differential histotype diagnosis could be obtained.
  • Starting from this premise OCT can also allows radioguided surgery in tumours non expressing SSR.
  • Finally a relevant clinical role can be defined in the a priori recruitment and as marker of therapeutic efficacy in all the therapeutic strategies utilizing SSR, both in malignant and benign diseases.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20168284.001).
  • [ISSN] 1824-4785
  • [Journal-full-title] The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of Radiopharmaceutical Chemistry and Biology
  • [ISO-abbreviation] Q J Nucl Med Mol Imaging
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Receptors, Somatostatin; 0 / indium-111-octreotide; 51110-01-1 / Somatostatin; RWM8CCW8GP / Octreotide
  • [Number-of-references] 98
  •  go-up   go-down


44. Kaltsas G, Androulakis II, de Herder WW, Grossman AB: Paraneoplastic syndromes secondary to neuroendocrine tumours. Endocr Relat Cancer; 2010 Sep;17(3):R173-93
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Paraneoplastic syndromes secondary to neuroendocrine tumours.
  • Neuroendocrine tumours may be either benign or malignant tumours, and have the ability to synthesise and secrete biologically active substances characteristic of the cell of origin that can cause distinct clinical syndromes.
  • The term 'paraneoplastic syndromes' (PNSs) is used to denote syndromes secondary to substances secreted from tumours not related to their specific organ or tissue of origin and/or production of autoantibodies against tumour cells; such syndromes are mainly associated with hormonal and neurological symptoms.
  • Appreciation of the presence of such syndromes is important as clinical presentation, if not identified, may delay the diagnosis of the underlying neoplasia.
  • Conversely, early recognition can allow for more rapid diagnosis, particularly as the coexistence of a neoplasm with a clinical or biochemical marker offers an additional determinant of tumour status/progression.
  • Their diagnosis involves a multidisciplinary approach, and detailed endocrinological, neurological, radiological and histological studies are required.
  • Correct diagnosis is essential as the treatment of choice will be different for each disorder, particularly in the case of malignant tumours; it is therefore important to develop appropriate means to correctly identify and localise these tumours.
  • Clinical awareness and the incorporation into clinical practise of (111)In-octreotide scintigraphy, chromogranin A and other evolving biochemical marker measurement techniques have substantially contributed to the identification of patients harbouring such syndromes.
  • Disease-specific medical therapies are mandatory in order to prevent recurrence and/or further tumour growth.
  • [MeSH-major] Neuroendocrine Tumors / complications. Paraneoplastic Syndromes / etiology

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20530594.001).
  • [ISSN] 1479-6821
  • [Journal-full-title] Endocrine-related cancer
  • [ISO-abbreviation] Endocr. Relat. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  •  go-up   go-down


45. Booij KA, van Eeden S, Ghazi Hosseini E, ten Kate FJ, Aronson DC: [An unusual presentation of a periappendicular infiltrate]. Ned Tijdschr Geneeskd; 2008 Sep 27;152(39):2133-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The clinical aspect, radiological investigations and peroperative aspect of the appendix were not conclusive but nevertheless a neuroendocrine tumour (carcinoid tumour) of the appendix was suspected.
  • After ileocaecal resection and resection of pathological lymph nodes, histopathological evaluation revealed the diagnosis: a periappendicular mass without any sign of malignancy.
  • In retrospect, ileocaecal resection was performed for a benign disease.
  • [MeSH-minor] Abdominal Pain / etiology. Adolescent. Diagnosis, Differential. Humans. Male

  • MedlinePlus Health Information. consumer health - Appendicitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18856031.001).
  • [ISSN] 0028-2162
  • [Journal-full-title] Nederlands tijdschrift voor geneeskunde
  • [ISO-abbreviation] Ned Tijdschr Geneeskd
  • [Language] dut
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


46. Vias M, Massie CE, East P, Scott H, Warren A, Zhou Z, Nikitin AY, Neal DE, Mills IG: Pro-neural transcription factors as cancer markers. BMC Med Genomics; 2008 May 19;1:17
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The aberrant transcription in cancer of genes normally associated with embryonic tissue differentiation at various organ sites may be a hallmark of tumour progression.
  • For example, neuroendocrine differentiation is found more commonly in cancers destined to progress, including prostate and lung.
  • We sought to identify proteins which are involved in neuroendocrine differentiation and differentially expressed in aggressive/metastatic tumours.
  • RESULTS: Expression arrays were used to identify up-regulated transcripts in a neuroendocrine (NE) transgenic mouse model of prostate cancer.
  • Using quantitative RT-PCR and immuno-histochemistry we showed that these same genes were highly expressed in castrate resistant, metastatic LNCaP cell-lines.
  • The expression of these pro-neural transcripts effectively segregates metastatic from localised prostate cancer and benign tissue as well as sub-clustering a variety of other human cancers.

  • COS Scholar Universe. author profiles.
  • antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurosci. 2000 Jan 1;20(1):283-93 [10627606.001]
  • [Cites] J Cell Sci. 2004 Sep 1;117(Pt 19):4411-22 [15304527.001]
  • [Cites] Urology. 2000 Dec 20;56(6):1011-5 [11113749.001]
  • [Cites] Science. 2004 Sep 3;305(5689):1466-70 [15353804.001]
  • [Cites] Pediatr Blood Cancer. 2005 Jan;44(1):77-84 [15390277.001]
  • [Cites] Genome Biol. 2004;5(10):R80 [15461798.001]
  • [Cites] Cancer Res. 2004 Dec 15;64(24):9209-16 [15604294.001]
  • [Cites] Eur Urol. 2005 Feb;47(2):147-55 [15661408.001]
  • [Cites] Clin Lung Cancer. 2005 Jan;6(4):227-36 [15694015.001]
  • [Cites] Exp Cell Res. 2005 Jun 10;306(2):343-8 [15925590.001]
  • [Cites] J Natl Cancer Inst. 2005 Sep 7;97(17):1287-96 [16145049.001]
  • [Cites] Cancer Cell. 2005 Nov;8(5):393-406 [16286247.001]
  • [Cites] Br J Cancer. 1991 Aug;64(2):333-8 [1654075.001]
  • [Cites] Urol Oncol. 2006 Jul-Aug;24(4):313-7 [16818183.001]
  • [Cites] Int J Oncol. 2006 Sep;29(3):567-75 [16865272.001]
  • [Cites] Cancer Res. 2006 Aug 15;66(16):7889-98 [16912162.001]
  • [Cites] Prostate. 2007 Feb 1;67(2):190-202 [17044078.001]
  • [Cites] BMC Bioinformatics. 2007;8:9 [17214880.001]
  • [Cites] Int J Oncol. 2007 Aug;31(2):461-6 [17611704.001]
  • [Cites] Br J Urol. 1991 Sep;68(3):258-62 [1913066.001]
  • [Cites] Hum Pathol. 1987 Feb;18(2):185-94 [3804322.001]
  • [Cites] Am J Surg Pathol. 1984 May;8(5):345-56 [6203413.001]
  • [Cites] Cancer Res. 1995 Jul 15;55(14):3068-72 [7541709.001]
  • [Cites] Prostate. 1996 Feb;28(2):129-35 [8604394.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 May 13;94(10):5355-60 [9144241.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Dec 8;95(25):14863-8 [9843981.001]
  • [Cites] J Biol Chem. 2001 Aug 10;276(32):30467-74 [11399758.001]
  • [Cites] J Exp Med. 2001 Oct 1;194(7):991-1002 [11581320.001]
  • [Cites] Ann Oncol. 2001;12 Suppl 2:S141-4 [11762342.001]
  • [Cites] Development. 2002 Apr;129(7):1553-67 [11923194.001]
  • [Cites] J Urol. 2002 Sep;168(3):1204-11 [12187268.001]
  • [Cites] Dev Dyn. 2003 Apr;226(4):675-89 [12666205.001]
  • [Cites] Cancer Lett. 2003 Aug 20;198(2):229-39 [12957362.001]
  • [Cites] Mod Pathol. 2004 Feb;17(2):222-9 [14657947.001]
  • [Cites] Br J Cancer. 2004 Feb 9;90(3):665-71 [14760382.001]
  • [Cites] Int J Oncol. 2004 Apr;24(4):943-9 [15010834.001]
  • [Cites] Am J Clin Pathol. 2004 Jul;122(1):100-5 [15272537.001]
  • [Cites] Development. 2000 Jul;127(13):2933-43 [10851137.001]
  • (PMID = 18489756.001).
  • [ISSN] 1755-8794
  • [Journal-full-title] BMC medical genomics
  • [ISO-abbreviation] BMC Med Genomics
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / G0500966; United States / NCRR NIH HHS / RR / K26 RR017595; United States / NCI NIH HHS / CA / R01 CA096823; United States / NCI NIH HHS / CA / R56 CA096823
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2413260
  •  go-up   go-down


47. Wilson HM: Chronic subacute bowel obstruction caused by carcinoid tumour misdiagnosed as irritable bowel syndrome: a case report. Cases J; 2009;2(1):78
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chronic subacute bowel obstruction caused by carcinoid tumour misdiagnosed as irritable bowel syndrome: a case report.
  • BACKGROUND: Carcinoid tumours are well-differentiated neuroendocrine tumours with secretory properties.
  • This ileal lesion was removed at laparotomy and identified as a carcinoid tumour.
  • CONCLUSION: This case highlights the issue of misdiagnosis of intestinal malignancy as the benign condition of irritable bowel syndrome.
  • There have been several other references to this happenstance in the literature, and the problem is reflected in the percentage of patients with widespread disease at the time of diagnosis.
  • Prognosis in this condition can be dramatically improved with early diagnosis, and surgical management at this stage is often curative.
  • For this reason it is imperative to keep this differential diagnosis in the back of one's mind when assessing patients presenting with symptoms of intermittent partial bowel obstruction.
  • The clinical presentation of this tumour, along with investigation and management of these cases, is discussed here.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neuroendocrinology. 2008;87(1):8-19 [18097129.001]
  • [Cites] Radiographics. 2007 Jan-Feb;27(1):237-57 [17235010.001]
  • [Cites] Gut. 2005 Jun;54 Suppl 4:iv1-16 [15888809.001]
  • [Cites] J Am Coll Surg. 1998 Jul;187(1):88-92; discussion 92-3 [9660030.001]
  • [Cites] Adv Exp Med Biol. 2000;482:329-37 [11192593.001]
  • [Cites] Cancer. 1997 Mar 15;79(6):1086-93 [9070484.001]
  • [Cites] J Clin Gastroenterol. 1993 Mar;16(2):123-9 [8463615.001]
  • [Cites] Am J Surg. 1995 Jan;169(1):36-42; discussion 42-3 [7817996.001]
  • [Cites] Arch Pathol Lab Med. 2003 Sep;127(9):1200-3 [12946222.001]
  • [Cites] Ann Oncol. 1997 Jul;8(7):685-90 [9296223.001]
  • (PMID = 19161610.001).
  • [ISSN] 1757-1626
  • [Journal-full-title] Cases journal
  • [ISO-abbreviation] Cases J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2633323
  •  go-up   go-down


48. Ruiz-Tovar J, Priego P, Martínez-Molina E, Morales V, Sanjuanbenito A, Lobo E: Pancreatic neuroendocrine tumours. Clin Transl Oncol; 2008 Aug;10(8):493-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pancreatic neuroendocrine tumours.
  • INTRODUCTION: Pancreatic neuroendocrine tumours (PNT) are infrequent epithelial neoplasms associated with a better outcome than pancreatic adenocarcinoma.
  • Eight patients presented with nonfunctional tumours.
  • In six patients, the tumour was not resected.
  • 39 cases showed benign histologic features and ten malignant ones.
  • Actuarial mean survival was 163 months and was longer in insulinomas, in those tumours completely resected and in tumours with benign histological features.
  • CONCLUSION: Conservative surgery of the pancreas is preferred, but aggressive surgery is indicated when the primary tumour can be controlled.
  • [MeSH-major] Neuroendocrine Tumors / mortality. Pancreatic Neoplasms / mortality
  • [MeSH-minor] Adolescent. Adult. Aged. Female. Gastrinoma / pathology. Gastrinoma / surgery. Glucagonoma / pathology. Glucagonoma / surgery. Humans. Insulinoma / pathology. Insulinoma / surgery. Male. Middle Aged. Neoplasm Staging. Pancreatic Fistula / pathology. Pancreatic Fistula / surgery. Pancreaticoduodenectomy. Prognosis. Retrospective Studies. Survival Rate. Treatment Outcome. Vipoma / pathology. Vipoma / surgery

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2002 Jun 1;20(11):2633-42 [12039924.001]
  • [Cites] Surgery. 2003 Dec;134(6):1057-63; discussion 1063-5 [14668741.001]
  • [Cites] Ann Surg. 2007 Feb;245(2):273-81 [17245182.001]
  • [Cites] Am J Surg. 2007 May;193(5):610-3; discussion 613 [17434366.001]
  • [Cites] Arch Surg. 2006 Oct;141(10):1000-4; discussion 1005 [17043278.001]
  • [Cites] Rev Esp Enferm Dig. 2007 Apr;99(4):218-22 [17590104.001]
  • [Cites] Am J Surg. 1994 Dec;168(6):627-9; discussion 629-30 [7978008.001]
  • [Cites] Curr Probl Surg. 1994 Feb;31(2):77-156 [7904550.001]
  • [Cites] Surgery. 2001 Dec;130(6):1078-85 [11742342.001]
  • (PMID = 18667380.001).
  • [ISSN] 1699-048X
  • [Journal-full-title] Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  • [ISO-abbreviation] Clin Transl Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


49. Hicks RJ: Use of molecular targeted agents for the diagnosis, staging and therapy of neuroendocrine malignancy. Cancer Imaging; 2010;10 Spec no A:S83-91
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Use of molecular targeted agents for the diagnosis, staging and therapy of neuroendocrine malignancy.
  • Imaging of neuroendocrine tumours (NET) poses significant challenges because of the heterogeneous biology of the tumours that are represented by this class of neoplasia.
  • NET can range from benign lesions to highly aggressive cancers.
  • Structural imaging techniques have suboptimal sensitivity in most published series and diagnosis is often delayed until metastatic disease is present.
  • Routine use of single-photon emission computed tomography (SPECT) and particularly of hybrid SPECT/computed tomography (CT) has significantly improved localisation of tumour sites and evaluation of somatostatin receptor (SSTR) expression, which is important for predicting the likelihood of response to somatostatin analogues (SSA).
  • Functioning tumours also require substrates for their secreted products.
  • This can be exploited for NET imaging with amine precursor uptake being imaged using [(18)F]3,4-dihydrophenylalanine and serotonin-secreting tumours being sensitively detected using [(11)C]5-hydroxytryptamine.
  • [MeSH-major] Neuroendocrine Tumors / diagnosis. Radiopharmaceuticals / therapeutic use. Receptors, Somatostatin / analysis
  • [MeSH-minor] 3-Iodobenzylguanidine / therapeutic use. Humans. Neoplasm Staging. Positron-Emission Tomography. Tomography, Emission-Computed, Single-Photon. Tomography, X-Ray Computed

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Nucl Med Mol Imaging. 2002 Dec;29(12):1571-80 [12458390.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2010 Oct;37(10):1869-75 [20445977.001]
  • [Cites] Neuroendocrinology. 2004;80 Suppl 1:12-5 [15477709.001]
  • [Cites] Cancer. 1991 Jul 15;68(2):227-32 [1712661.001]
  • [Cites] Metabolism. 1992 Sep;41(9 Suppl 2):83-6 [1355591.001]
  • [Cites] J Nucl Med. 1993 Jun;34(6):873-8 [8389841.001]
  • [Cites] J Nucl Med. 1995 Jan;36(1):1-6 [7799058.001]
  • [Cites] Digestion. 1994;55 Suppl 3:54-9 [7698538.001]
  • [Cites] J Clin Oncol. 1998 Jul;16(7):2534-41 [9667275.001]
  • [Cites] Nucl Med Commun. 1998 Aug;19(8):735-42 [9751927.001]
  • [Cites] J Nucl Med. 2005 Jan;46 Suppl 1:67S-75S [15653654.001]
  • [Cites] J Nucl Med. 2005 Jan;46 Suppl 1:83S-91S [15653656.001]
  • [Cites] Ann N Y Acad Sci. 2006 Aug;1073:104-11 [17102077.001]
  • [Cites] Best Pract Res Clin Endocrinol Metab. 2007 Mar;21(1):43-68 [17382265.001]
  • [Cites] Exp Clin Endocrinol Diabetes. 2007 Mar;115(3):155-9 [17427102.001]
  • [Cites] Hematol Oncol Clin North Am. 2007 Jun;21(3):575-81; x [17548041.001]
  • [Cites] Endocr Relat Cancer. 2007 Jun;14(2):221-32 [17639039.001]
  • [Cites] Virchows Arch. 2007 Aug;451 Suppl 1:S9-27 [17684761.001]
  • [Cites] Virchows Arch. 2007 Oct;451(4):757-62 [17674042.001]
  • [Cites] Lancet Oncol. 2008 Jan;9(1):61-72 [18177818.001]
  • [Cites] J Clin Oncol. 2008 Mar 20;26(9):1489-95 [18349401.001]
  • [Cites] J Nucl Med. 2008 Apr;49(4):573-86 [18344441.001]
  • [Cites] J Clin Oncol. 2008 May 1;26(13):2124-30 [18445841.001]
  • [Cites] Cancer. 2008 Jun;112(11):2447-55 [18383518.001]
  • [Cites] J Clin Oncol. 2008 Jul 10;26(20):3403-10 [18612155.001]
  • [Cites] J Clin Oncol. 2008 Sep 10;26(26):4311-8 [18779618.001]
  • [Cites] Q J Nucl Med Mol Imaging. 2008 Dec;52(4):334-40 [18480742.001]
  • [Cites] J Natl Compr Canc Netw. 2009 Jul;7(7):712-47 [19635226.001]
  • [Cites] J Clin Oncol. 2009 Oct 1;27(28):4656-63 [19704057.001]
  • [Cites] Cancer Biother Radiopharm. 2009 Oct;24(5):527-33 [19877882.001]
  • [Cites] Aliment Pharmacol Ther. 2010 Jan 15;31(2):169-88 [19845567.001]
  • [Cites] J Clin Oncol. 2010 Apr 1;28(10):1652-9 [20194865.001]
  • [Cites] Virchows Arch. 2010 Jun;456(6):595-7 [20422210.001]
  • [Cites] Curr Opin Oncol. 2010 Jul;22(4):381-6 [20473165.001]
  • [Cites] Ann Surg Oncol. 2010 Sep;17(9):2427-43 [20217257.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2003 Jan;30(1):9-15 [12483404.001]
  • (PMID = 20880795.001).
  • [ISSN] 1470-7330
  • [Journal-full-title] Cancer imaging : the official publication of the International Cancer Imaging Society
  • [ISO-abbreviation] Cancer Imaging
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0 / Receptors, Somatostatin; 35MRW7B4AD / 3-Iodobenzylguanidine
  • [Other-IDs] NLM/ PMC2967140
  •  go-up   go-down


50. Niederle MB, Hackl M, Kaserer K, Niederle B: Gastroenteropancreatic neuroendocrine tumours: the current incidence and staging based on the WHO and European Neuroendocrine Tumour Society classification: an analysis based on prospectively collected parameters. Endocr Relat Cancer; 2010 Dec;17(4):909-18
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gastroenteropancreatic neuroendocrine tumours: the current incidence and staging based on the WHO and European Neuroendocrine Tumour Society classification: an analysis based on prospectively collected parameters.
  • As incidence data on gastroenteropancreatic neuroendocrine tumours (GEP-NETs) have so far only been retrospectively obtained and based on inhomogeneous material, we conducted a prospective study in Austria collecting all newly diagnosed GEP-NETs during 1 year.
  • Using the current WHO classification, the tumor, nodes, metastases (TNM) staging and Ki67 grading and the standard diagnostic procedure proposed by the European Neuroendocrine Tumor Society (ENETS), GEP-NETs from 285 patients (male: 148; female: 137) were recorded.
  • Patients with appendiceal tumours were significantly younger than patients with tumours in any other site.
  • About 46.0% were classified as benign, 15.4% as uncertain, 31.9% as well differentiated malignant and 6.7% as poorly differentiated malignant.
  • Patients with benign or uncertain tumours were significantly younger than patients with malignant tumours.
  • Among the malignant tumours of the digestive tract, 1.49% arose from neuroendocrine cells.
  • NETs of the digestive tract are more common than previously reported; the majority show benign behaviour, are located in the stomach and are well differentiated.
  • G3 tumours are very rare.
  • [MeSH-major] Gastrointestinal Neoplasms / pathology. Neuroendocrine Tumors / pathology. Pancreatic Neoplasms / pathology
  • [MeSH-minor] Adult. Age Factors. Austria / epidemiology. Female. Histocytochemistry. Humans. Incidence. Male. Middle Aged. Neoplasm Staging / methods. Prospective Studies

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20702725.001).
  • [ISSN] 1479-6821
  • [Journal-full-title] Endocrine-related cancer
  • [ISO-abbreviation] Endocr. Relat. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


51. Parini U, Nardi M Jr, Loffredo A, Fabozzi M, Roveroni M: Laparoscopic resection of duodenal gangliocytic paraganglioma. A case report. Chir Ital; 2007 Jul-Aug;59(4):551-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laparoscopic resection of duodenal gangliocytic paraganglioma. A case report.
  • Paraganglioma is an exceedingly rare tumour of the duodenum that arises in close proximity to the ampulla of Vater.
  • To date a total of 133 cases of duodenal paraganglioma have been reported in the literature; of these, 27 (20%) were histologically gangliocytic paragangliomas.
  • This neoplasm generally behaves in a benign fashion, although instances of recurrence and/or lymph node metastasis have been described.
  • The treatment consists in endoscopic polypectomy or surgical resection in relation to the histological features and the macroscopic extent of the neoplasm.
  • We present a case of a benign duodenal gangliocytic paraganglioma treated by a laparo-endoscopic approach.
  • We report a case of gangliocytic paraganglioma in a 75-year-old woman admitted to the General Surgery Division of Aosta Regional Hospital (Aosta-Italy), complaining of melaena and anaemia.
  • Upper gastrointestinal endoscopy followed by enteroscopy with a video-capsula, revealed a pedunculated neoplasm in the second portion of the duodenum, with ulceration of the overlying mucosa.
  • Multiple biopsies were performed during the endoscopic examination and showed the cellular pattern of benign paraganglioma.
  • After stabilisation of the patient's clinical status, we performed a resection of the neoplasm via a laparoscopic transduodenal approach and a concomitant intraoperative duodenoscopy.
  • The histological features showed a gangliocytic paraganglioma without a malignant cell pattern.
  • The size of the neoplasm was 4 cm.
  • The patient is currently in good health without any tumour recurrence.
  • Transduodenal laparoscopic resection with intraoperative duodenoscopy is a valuable treatment for benign gangliocytic paraganglioma of the duodenum which is unresectable by upper gastrointestinal endoscopy.
  • This approach affords the advantages of the minimally invasive technique and fulfils the surgical tenets of the open transduodenal approach, if en bloc resection of the neoplasm with the adjacent duodenal wall is performed.
  • [MeSH-major] Duodenal Neoplasms / surgery. Laparoscopy. Paraganglioma / surgery

  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17966779.001).
  • [ISSN] 0009-4773
  • [Journal-full-title] Chirurgia italiana
  • [ISO-abbreviation] Chir Ital
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


52. Agha A, Iesalnieks I, Glockzin G, Schlitt HJ: [Surgical therapy for adrenal tumours]. Zentralbl Chir; 2010 Jun;135(3):233-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Surgical therapy for adrenal tumours].
  • Four endoscopic and four open accesses are available for the surgery of adrenal tumours.
  • The decision to use one of the available techniques depends on tumour size, body mass index, previous abdominal surgery and the experience of the surgeon.
  • Conventional surgery should be used if malignancy is suspected, especially for tumours larger than 6 cm.
  • In individual cases, even tumours up to 10 cm can be operated laparoscopically if there is no suspicion of invasive growth or lymphatic metastases.
  • The retroperitoneoscopic and laparoscopic accesses for benign adrenal tumours up to 6 cm are considered to be equivalent.
  • The surgeon should also be able to approach adrenal tumours conventionally.
  • [MeSH-major] Adrenal Gland Neoplasms / surgery. Adrenocortical Adenoma / surgery. Neuroendocrine Tumors / surgery
  • [MeSH-minor] Adrenal Glands / pathology. Adrenalectomy / methods. Diagnosis, Differential. Humans. Laparoscopy / methods. Minimally Invasive Surgical Procedures / methods

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Georg Thieme Verlag Stuttgart , New York.
  • (PMID = 20549586.001).
  • [ISSN] 1438-9592
  • [Journal-full-title] Zentralblatt für Chirurgie
  • [ISO-abbreviation] Zentralbl Chir
  • [Language] ger
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Review
  • [Publication-country] Germany
  •  go-up   go-down


53. Matyja E, Maksymowicz M, Grajkowska W, Olszewski W, Zieliński G, Bonicki W: Spindle cell oncocytoma of the adenohypophysis - a clinicopathological and ultrastructural study of two cases. Folia Neuropathol; 2010;48(3):175-84
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spindle cell oncocytoma of the adenohypophysis - a clinicopathological and ultrastructural study of two cases.
  • Spindle cell oncocytoma (SCO) of the pituitary gland is a relatively recently established, very rare subtype of adenohypophysis tumours that was introduced as a distinct clinicopathological entity in the fourth edition of WHO classification of the central nervous system tumours (2007).
  • It is non-endocrine neoplasm of the anterior pituitary that occurs in adults and usually follows a benign clinical course, corresponding to WHO grade I.
  • Because of their rarity, the pathogenesis and natural history of these tumours have not been fully characterized.
  • One patient presented with tumour recurrence 3 years after undergoing the previous surgical removal of tumour, which was initially misdiagnosed as schwannoma.
  • The first tumour was removed by transsphenoidal surgery and the second one by frontal craniotomy.
  • Histologically and immunohistochemically, both tumours displayed the features typical for SCO of the pituitary.
  • The tumour cells exhibited immunoreactivity for S-100 protein, galectin-3, vimentin and epithelial membrane antigen but they were negative for GFAP, anterior pituitary neuroendocrine markers (prolactin, growth hormone, TSH, ACTH, FSH, LH), chromogranin, synaptophysin, cytokeratin CK (AE1/AE3), smooth muscle actin, desmin, CD34 and CD68.
  • Ultrastructurally, the tumour cells were rich in mitochondria with lamellar cristae.
  • Moreover, in Case 2 some tumour cells showed a number of giant mitochondria with severely destructed internal matrix.
  • Spindle cell oncocytoma of the anterior pituitary is often misdiagnosed entity of uncertain histogenesis.
  • It should be considered in the differential diagnosis of various sellar-region lesions of oncocytic morphology.

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20925001.001).
  • [ISSN] 1509-572X
  • [Journal-full-title] Folia neuropathologica
  • [ISO-abbreviation] Folia Neuropathol
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


54. Kolb A, Kleeff J, Frohlich B, Werner J, Friess H, Büchler MW: Resection of the intrapancreatic bile duct preserving the pancreas. J Hepatobiliary Pancreat Surg; 2009;16(1):31-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Benign neoplasms of the distal bile duct are rare, but pose a therapeutic challenge.
  • Here, we present a case of an intrapancreatic benign neuroendocrine tumor that was resected by performing a pancreas-preserving distal bile duct resection.
  • First, a duodenotomy was carried out and a probe was inserted into the pancreatic duct to avoid inadvertent injury.
  • The duodenal incision was closed, and reconstruction was performed by an end-to-side hepaticojejunostomy and a Roux-Y jejunojejunostomy.
  • In conclusion, pancreas-preserving distal bile duct resection might be an option for intrapancreatic benign lesions of the distal bile duct that would otherwise require a partial pancreaticoduodenectomy.
  • [MeSH-major] Carcinoma, Neuroendocrine / surgery. Pancreas / surgery. Pancreatic Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19089312.001).
  • [ISSN] 1436-0691
  • [Journal-full-title] Journal of hepato-biliary-pancreatic surgery
  • [ISO-abbreviation] J Hepatobiliary Pancreat Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


55. Koroscil TM, McDonald S, Stutes S, Vila RJ: Use of fluorine-18-labelled deoxyglucose positron emission tomography with computed tomography to localize a paraganglioma in pregnancy. South Med J; 2010 Dec;103(12):1238-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Use of fluorine-18-labelled deoxyglucose positron emission tomography with computed tomography to localize a paraganglioma in pregnancy.
  • The patient underwent a laparotomy during the second trimester with successful removal of a benign paraganglioma.
  • [MeSH-major] Adrenal Gland Neoplasms / radiography. Paraganglioma / radiography. Pheochromocytoma / radiography. Pregnancy Complications, Neoplastic / radiography
  • [MeSH-minor] Adult. Diagnosis, Differential. Female. Fluorodeoxyglucose F18. Humans. Magnetic Resonance Imaging. Positron-Emission Tomography. Pregnancy. Tomography, X-Ray Computed


56. Gil da Costa RM, Rema A, Pires MA, Gärtner F: Two canine Merkel cell tumours: immunoexpression of c-KIT, E-cadherin, beta-catenin and S100 protein. Vet Dermatol; 2010 Apr;21(2):198-201
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Two canine Merkel cell tumours: immunoexpression of c-KIT, E-cadherin, beta-catenin and S100 protein.
  • Canine Merkel cell tumours are rare neuroendocrine neoplasms that show a relatively benign biological behaviour when compared with their human counterparts.
  • This report describes the histopathological and immunohistochemical features of two such tumours.
  • The tumours' immunoreactivity profile was studied with respect to different cellular molecules including chromogranin A (CGA), neurone-specific enolase (NSE), S100 protein, c-KIT, the cytokeratins (CKs) detected by pancytokeratin (AE1/AE3) antibodies (i.e. high molecular weight CKs 1, 2, 3, 4, 5, 6, 10, 14, 15 and 16, and low molecular weight CKs 7, 8 and 19) and three markers proposed to correlate with increased malignancy in human tumours: E-cadherin, beta-catenin and p63 protein.
  • In both lesions, tumour cells were positive for cytokeratins, CGA, NSE, S100 and c-KIT.
  • These results suggest that the generally benign behaviour of canine Merkel cell tumours, when compared with their human counterparts, may be partly explained by the conservation of important intercellular adhesion molecules such as E-cadherin and beta-catenin.
  • Additionally, expression of S100 but not of the p63 protein suggests that these canine tumours present a trend towards neural, rather than basal, epithelial differentiation and do not readily compare with human Merkel cell tumours.
  • [MeSH-major] Cadherins / metabolism. Carcinoma, Merkel Cell / metabolism. Dog Diseases / diagnosis. Proto-Oncogene Proteins c-kit / metabolism. S100 Proteins / metabolism. beta Catenin / metabolism
  • [MeSH-minor] Animals. Biomarkers, Tumor / metabolism. Dogs. Female. Gene Expression Regulation, Neoplastic / physiology. Male

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19706008.001).
  • [ISSN] 1365-3164
  • [Journal-full-title] Veterinary dermatology
  • [ISO-abbreviation] Vet. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cadherins; 0 / S100 Proteins; 0 / beta Catenin; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  •  go-up   go-down


57. Adam N, Lim SS, Ananda V, Chan SP: VIPoma syndrome: challenges in management. Singapore Med J; 2010 Jul;51(7):e129-32
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Vasoactive intestinal peptide-producing tumour (VIPoma) or Verner-Morrison syndrome is a very rare neuroendocrine tumour.
  • It occurs in less than ten percent of all pancreatic islet cell tumours, and about 70 percent to 80 percent of these tumours originate from the pancreas.
  • Diagnosis is characteristically delayed.
  • It may be curative in forty percent of patients with benign and non-metastatic disease.
  • Somatostatin analogues improve hormone-mediated symptoms, reduce tumour bulk and prevent local and systemic effects.
  • We present a female patient with VIPoma syndrome, which had metastasised to the liver at diagnosis.
  • [MeSH-minor] Catheter Ablation / methods. Combined Modality Therapy. Disease Progression. Female. Follow-Up Studies. Humans. Middle Aged. Neoplasm Invasiveness / pathology. Neoplasm Staging. Octreotide / therapeutic use. Time Factors. Treatment Outcome






Advertisement